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ABSTRACT 
Optic neuropathy, as a result of various factors, is a leading cause of blindness in the world. 
The early diagnosis of optic nerve damage can aid therapeutic intervention, and experimental 
studies characterizing relevant diagnostic tools in different optic neuropathy models are 
currently lacking. In order to address this gap in current scientific literature, we aim to 
validate the following overarching hypothesis in this dissertation. 
The progression of optic neuropathy as a result of direct and indirect injury to the optic 
nerve can be reliably assessed using non-invasive functional and structural analytical 
tools. 
In order to verify this hypothesis, we have conceived and implemented the following specific 
aims. 
Specific Aim I: To characterize optic nerve structure and function using non-invasive tools in 
healthy C57/bl6 mice. 
Specific Aim II: To evaluate optic nerve status in C57/bl6 mice with experimentally induced 
Parkinson’s disease, as a model of indirect injury to the optic nerve.  
Specific Aim III: To evaluate optic nerve status in C57/bl6 mice following blast injury, as a 
model of direct injury to the optic nerve. 
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CHAPTER I. GENERAL INTRODUCTION 
Dissertation Organization 
An alternative format has been adopted for this dissertation; it includes modified versions of 
manuscripts either accepted or to be submitted for publication. The dissertation contains a 
general introduction (Chapter I), 3 research papers (Chapters II-IV), and a general conclusion 
(Chapter V). References from all sections are combined together at the end of the conclusion. 
Prior to the introduction, the central hypothesis governing the study is elucidated. The 
general introduction consists of 3 sections. The first section reviews the current non-invasive 
imaging routines for the retina and optic nerve and their utility in monitoring disease 
progression. The second section reviews Parkinson’s disease, the prevalent visual symptoms, 
and current non-invasive imaging techniques. The third section reviews traumatic brain 
injury resulting from blast exposure, the prevalent visual symptoms, and the current non-
invasive imaging techniques. Chapter II titled “Characterization of structure and function of 
the mouse retina using pattern electroretinography, pupil light reflex and optical coherence 
tomography” is a manuscript accepted for publication at the journal Veterinary 
Ophthalmology. Chapter III titled “Protein kinase C delta mediates retinal ganglion cell 
function loss following MPTP treatment in mice” is a manuscript prepared for submission to 
the journal Investigative Ophthalmology and Visual Sciences. Chapter IV titled “Retina and 
optic nerve damage in an experimental rodent model of blast-mediated traumatic brain 
injury” is a manuscript prepared for submission to the journal Investigative Ophthalmology 
and Visual Sciences. 
Visual information is transmitted from the photoreceptors to the final output cells of the 
retina, the retinal ganglion cells (RGC). The axons of the RGC bundle together to form the 
optic nerve that projects to the primary visual cortex via the lateral geniculate nucleus. The 
optic nerve is susceptible to damage by various factors, such as ischemia, compression, 
inflammation, trauma, toxins, and nutrient deficiency, which can cause visual dysfunction 
and, eventually, blindness. The optic nerve is also vulnerable to degeneration as a result of 
central nervous system (CNS) diseases, whose primary pathology is observed elsewhere. 
Currently, there are no means to clinically reverse optic nerve degeneration. Early diagnosis 
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can aid therapeutic interventions aimed at slowing RGC degeneration and maintaining their 
function. Further, the optic nerve is the most accessible region of the CNS and could provide 
an avenue to study disease processes affecting other regions of the CNS. The experimental 
study of CNS diseases and their impact on the retina and optic nerve could eventually 
provide means to monitor disease progression. With these goals in mind, it is crucial to 
define optic nerve degeneration in different disease models and standardize imaging 
techniques that can non-invasively monitor the structure and function of the retina and optic 
nerve. In the following pages, we review current methods of imaging the optic nerve 
structure and function; this is followed by reviews of Parkinson’s disease and traumatic brain 
injury as a result of blast exposure, two disease models that affect the anterior visual 
pathway.  
Literature Review I: Non-invasive imaging of the optic nerve 
Optic neuropathies are among the leading causes of blindness in the world and can manifest 
due to hereditary and acquired factors. Commonly observed pathological changes in optic 
neuropathy include optic nerve head (ONH) abnormalities and thinning of the retinal nerve 
fiber layer (RNFL) as a result of degeneration of RGCs or its axons1. However, structural 
changes are not always apparent, and optic nerve dysfunction might be the only indication of 
disease2. Currently, many techniques exist to monitor structure and function of the optic 
nerve non-invasively, and we review some of the most important here.  
Structural imaging 
Optical coherence tomography 
Optical coherence tomography (OCT) is a non-invasive biological imaging technique, 
earliest versions of which utilized low-coherence interferometry to provide two-dimensional 
images of the imaged tissue3.  The technique involves an optical beam that scans the retina 
and the magnitude and echo time delay of the backscattered light is measured. The low-
coherence interferometer has two arms, one which directs light on the sample and collects the 
returning backscattered light, and another mechanically controlled reference arm with a 
reflecting mirror varies time delay and measures interference4. Low-coherence interference 
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occurs when the distance travelled by light in the biological sample and the reference arm 
match to within the coherence length4. This early iteration of OCT, called time-domain OCT 
(TD-OCT), has been improved upon to utilize interference spectrum from light of different 
wavelengths using a stationary reference mirror. Image data is then acquired by a 
spectrometer that acts as a detector, which is then Fourier-transformed to extract depth 
information. This technique called Fourier-domain or spectral domain OCT (SD-OCT) has 
greater resolution and acquisition speed5. SD-OCT enables rapid imaging of the different 
retinal layers to monitor progression of diseases and the effects of treatment. Further, modern 
versions of the OCT (e.g., Spectralis, Heidelberg Engineering) also incorporate confocal 
scanning laser ophthalmoscopy (cSLO) into the same platform, enabling improved fundus 
imaging. SD-OCT has been extensively used to diagnose and monitor diseases including 
glaucoma6, retinitis pigmentosa7, and macular degeneration8. In addition, OCT has been used 
extensively in studying MS-associated optic neuritis4,9,10. SD-OCT can also be modified with 
adaptive optics and 78D lens for use in rodents11, enabling its use in experimental studies. 
Drawbacks of the system include problems with the automated segmentation of RNFL which 
might not exactly reflect actual retinal anatomy, especially in disease conditions. Further, 
media opacities, like cataracts, can affect the quality of the image obtained12.  
Diffusion tensor imaging 
Diffusion tensor imaging (DTI), a modification of magnetic resonance imaging (MRI), 
enables the study of axon degeneration. This technique utilizes the direction of water 
diffusion through white matter tracts for imaging. Diffusion proceeds faster along the 
direction of the fiber tract, while it is much slower in the direction perpendicular to the main 
axis of the tract. This directional selectivity of diffusion (called anisotropy) is affected when 
pathological processes affect the integrity of the white matter tract, thereby increasing 
diffusivity through the tract13. This variation in anisotropy can be used to determine optic 
nerve integrity. DTI axial diffusivity has been recently observed to be predictive of visual 
outcome following optic neuritis14. DTI has also been found sensitive to optic nerve damage 
in patients with multiple sclerosis15 and anterior ischemic optic neuropathy16. Further, recent 
experimental studies have characterized DTI use in mouse models of optic neuropathy17,18. 
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Since DTI is highly sensitive to microscopic motion, macroscopic movement can affect 
imaging; this is especially a problem with the optic nerve. Further, the optic nerve is 
surrounded by fat and bone, which require modifications of the imaging protocol to enhance 
sensitivity13.  
Scanning laser polarimetry 
Scanning laser polarimetry (SLP) is a technique that uses polarized light to detect RNFL 
thickness. The RNFL being birefringent, can retard polarized light; the degree of retardation 
is proportional to RNFL thickness, and is measured by SLP13. A recent study comparing 
OCT with SLP observed that OCT was better able to reflect RNFL thickening as a result of 
papilledema, while SLP was better at reflecting axon injury and associated swelling of the 
RNFL19. SLP has been used extensively in studying glaucoma progression20-22. Similar to the 
OCT, SLP can be affected by opacities in the ocular media, resulting in abnormal retardation. 
Further, birefringence can occur from other ocular components, thereby confounding the 
results23. 
Functional imaging 
Pattern-evoked electroretinography 
Pattern-evoked electroretinography (pERG) is an objective measure of RGC function and has 
been extensively used in the diagnosis of glaucoma24-28. The pERG stimulus consists of 
either bars or a checkerboard pattern, generally in black and white. Alternating reversal of the 
pattern at particular frequencies can elicit the pERG response, obtained either as a sinusoidal 
or transient waveform dependent on the frequency of reversal. This waveform consists of an 
initial negative component (N35), a prominent positive component (P50), and a delayed 
negative component (N95). The amplitude and latency of occurrence of the N95 component 
is indicative of RGC function29. The pERG response occurs as a result of RGC 
depolarization30 and this response is abolished by optic nerve transection31,32 or by 
pharmacologically eliminating action potentials using tetrodotoxin30. The technique has also 
been used in experimentally studying glaucoma and ocular hypertension in different animal 
models33-36. A disadvantage of this technique is that focal RGC loss or RNFL lesions may not 
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affect the full field pERG response; this can however be remedied by the use of multi-focal 
pERG techniques37. 
Chromatic pupil light reflex 
The chromatic pupil light reflex (cPLR) is a modification of the PLR technique that can be 
used to assess the functional integrity of the optic nerve38,39. This technique utilizes the 
differences in spectral sensitivities of rods, cones, and melanopsin-containing RGC to 
localize function loss within the anterior visual pathway. Stimulation of the eye with red (630 
nm) light activates a rod-cone mediated pupil light response, without activation of 
melanopsin mediated responses39.  The degree of contribution of rods vs. cones depends on 
the state of retinal adaptation, the spectral sensitivity of the photoreceptors in the species 
being studied and the brightness of the light. The rod-cone mediated pupil response requires 
a functional and well-organized dendritic arborization of RGCs to allow for signal processing 
of rod-cone input to the RGCs mediating PLR responses.  Stimulation of the eye with bright 
blue (480 nm) light can activate both a rod-cone mediated pupil response and a pupil 
response that is weighted towards an intrinsic melanopsin-mediated response and can provide 
information about the intracellular RGC status in PLR conducting RGCs34,38,40.  
Visual evoked potentials 
Conventional visual evoked potentials (VEP) measure the cortical response to stimulation of 
the visual field, and it is obtained in response to the central 30 degrees of the visual field13. 
Abnormalities in the VEP waveform can be indicative of retina and optic dysfunction. 
Increased latency of the cortical signal has been observed using different VEP protocols in 
patients with multiple sclerosis41,42. Similar to other visual field techniques, VEP measures 
full field responses which might not reflect focal defects. Multi-focal VEP is a variation of 
conventional VEP by which specific sectors of the visual field are stimulated enabling better 
localization of dysfunction43; this paradigm has been extensively used in studying 
glaucoma44-46.  
Literature Review II: Parkinson’s disease – more than just a motor disorder 
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Parkinson’s disease (PD) is the second most common neurodegenerative disease, following 
Alzheimer’s disease, with a high risk of incidence in the population above 60 years of age47. 
Diagnosis of PD is based on the expression of (a.) the cardinal motor symptoms—which 
include tremor, rigidity, postural instability and bradykinesia—of parkinsonism, originally 
expounded by James Parkinson in his description of the shaking palsy48; and (b.) the non-
motor symptoms associated with the disease, which include olfactory dysfunction, visual 
abnormalities, sleep disturbances, constipation, and autonomic dysfunction49. Although a 
number of factors, both genetic and environmental, have been identified to contribute to 
disease progression, the etiology of PD is still unclear50. An early-onset familial form of PD 
accounts for 5%-10% of all reported cases; mutations in α-synuclein, LRRK2, PINK1, parkin, 
and DJ1 have been reported in patients with this rare form of the disease51. However, the 
dominant manifestation accounting for majority of PD cases is the aging-related sporadic 
form of PD. Similar genetic mutations52 —especially those of α-synuclein53—and 
environmental factors50 have been implicated in the occurrence of late-onset PD. The 
primary pathology associated with PD is the progressive degeneration of mesencephalic 
dopaminergic neurons, present in the substantia nigra pars compacta (SNpc). Another 
defining characteristic is the occurrence of eosinophilic inclusions composed of α-synuclein, 
called Lewy bodies, in the neuronal cytoplasm54; these α-synuclein-positive Lewy bodies 
have been observed in the medullary, pontine, and mesencephalic nuclei of PD patients55. 
However, PD is a multisystem disorder, and these neuropathological correlates are also 
accompanied by degeneration in the peripheral and enteric nervous systems, and other 
regions of the central nervous system56,57.    
The mechanisms underlying PD pathology are still unclear. Currently, most therapeutic 
interventions aim to alleviate symptoms and do not treat underlying neurodegeneration. The 
primary line of treatment for PD involves oral administration of the dopamine precursor, 
levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) to increase the availability of dopamine. 
Many lines of evidence exist for the etiology of PD, with aging, environmental, and genetic 
factors contributing to pathology, although no single theory explains all characteristics of the 
disease 50,52,56,58,59. However, a certain degree of consensus has been achieved regarding the 
final mechanisms mediating dopaminergic cell death. Oxidative stress- and inflammation-
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mediated downstream cascades potentiate mitochondrial dysfunction and accumulation of 
mutant protein proteins, thereby mediating cell death via apoptosis or autophagy60,61. Much 
evidence in support of these cellular pathologies has been obtained from the study of various 
genetic and toxin-induced parkinsonian models62. Of particular relevance is the meperidine 
derivative, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic 
degeneration. It was discovered by Langston et al63 that meperidine accidentally 
contaminated with MPTP, which was used by drug addicts, resulted in the development of 
PD symptoms. MPP+, the active oxidized form of MPTP, inhibits mitochondrial complex I 
activity leading to the uncoupling of oxidative phosphorylation64. The high specificity of 
MPTP for dopaminergic neurons further facilitates study of the molecular mechanisms 
underlying PD62,65.  
Dopaminergic basis of PD 
The motor symptoms of PD are primarily attributed to hyperactivity of the subthalamic 
nucleus and internal globus pallidus as a result of dopaminergic neuron degeneration in the 
SNpc66. In particular, the ventrolateral tier of the SNpc is most susceptible to degeneration in 
PD67, leading to a loss of dopamine in the putamen. These nuclei are part of the basal ganglia 
subcortical system, one of the major circuits mediating thalamo-cortical transmission68. 
Dopamine, a member of the catecholamine family, is a major neurotransmitter within the 
CNS. Dopamine is synthesized from the amino acid L-tyrosine within dopaminergic neurons, 
primarily at the SNpc and ventral tegmental area (VTA) of the midbrain69. L-Tyrosine is first 
converted to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH), the 
rate-limiting enzyme70; dopamine is then obtained by decarboxylation of L-DOPA in the 
presence of DOPA decarboxylase71. Dopamine turnover is dependent upon the presence of 
the dopamine transporter (DAT), which facilitates dopamine reuptake and metabolism72.  
Currently, functional imaging of dopamine uptake, dopamine receptor binding, or the 
presynaptic targets of dopamine are predominantly used in monitoring the progression of PD; 
these include variations in radionuclide-based positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) methods and functional MRI (fMRI) 
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paradigms73,74. PET/SPECT studies of dopamine receptor binding have noted increased 
striatal D2 receptor binding and normal D1 receptor binding in early untreated PD 
patients74,75. Further, the supplementary motor area (SMA), in particular, the rostral pre-
SMA, and the dorsolateral prefrontal cortex in PD patients have been consistently observed 
to be hypoactive using PET/SPECT and fMRI studies76. Similar results have been reported 
by electrophysiological studies. Reduced amplitudes or shifted latencies were recorded in the 
early Bereitschaftspotential, contingent negative variation, and the N30 component of 
somatosensory evoked potentials (SSEP), all of which originate at the SMA76,77. Dopamine 
generated in the midbrain is transmitted by means of 3 pathways: the nigrostriatal, 
mesolimbic, and mesocortical pathways78. PD pathology as a result of striatal dopamine 
depletion is attributed to degeneration of the nigrostriatal pathway. In addition to the 
midbrain dopaminergic pathways, there exist 6 other pathways in the CNS, namely, the 
tuberoinfundibular, diencephalospinal, and incerto-hypothalamic pathways from the 
hypothalamic nuclei; the periventricular pathway arising from the mesencephalic and 
diencephalic periaqueductal and periventricular gray; the olfactory bulb pathway from the 
periglomerular cells; and the retinal pathway from amacrine cells of the inner nuclear layer79. 
Degeneration of these dopaminergic pathways could potentially account for some non-motor 
symptoms associated with PD.  
Non-motor symptoms of PD 
Although the motor symptoms of PD frequently define the disease, they are not the only 
characteristic of PD. A number of non-motor symptoms—including olfactory dysfunction, 
visual disturbances, gastrointestinal disorders, cognitive decline, and autonomic 
dysfunction—manifest during both the early and late stages of PD80,81. The pathological basis 
for the occurrence of these symptoms is yet to be clearly established. Dopaminergic 
deficiency and treatment have been found to contribute to a number of non-motor 
symptoms49,82. In addition, evidence for dysfunction in cholinergic83, noradrenergic84 and 
serotoninergic85,86 neurotransmitter systems are also present concurrently in PD and 
contribute to non-motor symptoms. Further, basal ganglia outputs are not exclusive to the 
motor cortex; extensive projections are made to various other regions of the cerebral cortex, 
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the hippocampus and the amygdala. In addition to the skeleto-motor circuit, frontal lobe 
targets of the basal ganglia include the oculomotor circuit, limbic circuit, and the prefrontal 
circuit68. Degeneration of these connections is also believed to contribute to the non-motor 
symptoms associated with PD87-89. It has been observed that some non-motor symptoms 
manifest much earlier clinically compared to the classic motor symptoms90,91. In an 
influential 2003 study, Braak et al57 dissected the occurrence of Lewy body pathology and 
the progression of sporadic PD into 6 stages. Stages 1 and 2 predominantly affect the medulla 
oblongata and the pontine tegmentum, with lesions in the dorsal IX/X motor nuclei, caudal 
raphe nuclei, and the reticular nuclei. In a recent observational study, vagus nerve SSEP were 
observed to have longer latencies in PD patients when compared to controls92. Midbrain 
lesions begin to occur in stage 3, and these lesions become extensive by stage 4; cortical 
lesions, predominantly in the mesocortex and allocortex, also appear in this stage. 
Neocortical lesions occur in stages 5 and 6, with degeneration in sensory association areas. 
These morphological observations support the early occurrence of non-motor symptoms such 
as olfactory dysfunction93,94, REM sleep behavior disorder95,96, cognitive 
impairment/dementia97-99, and autonomic dysfunction100-102, which can arise long before 
motor symptoms manifest. Study of these non-motor symptoms and their progression could 
provide insight into development of the disease, and it could provide a means to predict 
disease occurrence later in life, thereby acting as valuable diagnostic tools. Treatment of 
these symptoms could prove crucial in the improvement of the quality of life in PD patients. 
Visual dysfunction in PD 
The retina has several neuronal populations that utilize dopamine for neurotransmission. In 
particular, dopamine has been observed to be present in the interplexiform and amacrine cells 
of the retina103. Dopaminergic transmission is involved in mediating the lateral pathways of 
amacrine cells and horizontal cells104 and in modulating the center-surround functions of the 
retina that are crucial to receptive field organization105. Further, dopaminergic innervation 
could mediate adaptation to light and the concurrent transition from scotopic to photopic 
vision106,107.  
10 
 
Figure 1: Dopaminergic transmission in the retina. Light-mediated dopamine release in the 
retina can modulate the interactions between 
horizontal cells, amacrine cells, and RGC. Source: 
Nature Reviews Neuroscience 10, 495-506 (July 
2009)108. 
Visual dysfunction is frequently reported by PD 
patients, with impairment in primary and complex 
visual functions being commonly reported109,110. A 
correlation between disease severity and visual 
acuity loss was observed in a study on 39 PD 
patients111. A loss in visual contrast sensitivity112 
and spatiotemporal contrast sensitivity113, 114 has 
been reported among PD patients. A clinical study 
of 30 PD patients115 noted increased complaints of 
photophobia, dry eye, and hallucinations.  Furthermore these patients exhibited reduced blink 
rates and decreased convergence amplitudes. Visual hallucinations116-118, impaired color 
vision119,120, and difficulties in eye movement121-123 have been commonly reported among PD 
patients.  
Many studies in PD patients have observed alterations in different electrophysiological 
parameters, such as the pERG, electro-oculogram (EOG), flash ERG (FERG), and pattern 
VEP124-127. Further, recent studies have reported reduction in RNFL thickness using OCT, 
primarily in the macular region128,129. Peppe et al124,130 observed abnormal pERG amplitudes 
in their human PD patients, and these deficits were reversible by L-DOPA treatment. 
Another study using multifocal ERG reported a decrease in electrical activity in the foveal 
region of PD patients129. Similarly, experimental studies using MPTP and 6-OHDA 
injections in monkeys have found abnormalities in pattern VEP and pERG, which returned to 
normal with L-DOPA administration131,132. Further, morphological abnormalities of 
dopaminergic neurons have been observed in primates with experimentally induced PD133. In 
one study, post-mortem analysis of retinas revealed reduced dopamine content in PD patients 
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without L-DOPA treatment; however, among PD patients treated with L-DOPA, dopamine 
content was similar to those measured in controls134. These studies suggest a role for retinal 
dopamine in mediating visual dysfunction. However, it is unlikely that retinal dopaminergic 
deficiency alone is responsible for all observed symptoms; visual processing at the primary 
visual cortex and associated regions could also be affected86,135. 
Literature Review III – Blast exposure and traumatic brain injury 
Traumatic brain injury (TBI) is a debilitating condition that can lead to the development of 
significant cognitive and neurological symptoms, years after the event of injury. Currently, it 
is estimated that more than 1.5 million people in the U.S alone sustain some form of TBI 
every year. TBI can be further classified into mild, moderate, and severe based on the degree 
of injury sustained and the expression of specific clinical symptoms. Mild TBI (mTBI), 
frequently referred to as concussion, accounts for up to 85% of medically treated TBI in the 
U.S136. It includes any injury to the brain that induces an alteration in mental status leading to 
physical, behavioral, and cognitive symptoms. Loss of consciousness does not necessarily 
have to occur for the development of these symptoms137. In addition, mTBI can cause 
chronic disorders, with 25% of patients reporting post-concussive symptoms (PCS) or 
cognitive defects that persist beyond one year despite the absence of morphological brain 
abnormalities138. A prospective study of 123 patients with mTBI at 1 week and 3 months 
after injury revealed severe PCS at 1 week and a higher likelihood for memory and 
concentration problems at 3 months compared to trauma-matched controls139. Further, 
Vanderploeg et al140 reported the long-term prevalence of PCS with associated neurological 
and psychosocial disturbances in Vietnam-era veterans exposed to mTBI. Such mTBI has 
become of major concern, especially in light of the recent wars in Iraq and Afghanistan 
(Operation Iraqi Freedom [OIF] and Operation Enduring Freedom [OEF]). Due to 
advancements in armor and other protective gear, the incidence of severe penetrating injuries, 
which are usually fatal, has been greatly reduced. However, the frequent use of improvised 
explosive devices by insurgents in Afghanistan and Iraq has escalated the number of blast-
mediated injuries in soldiers. In fact, exposure to high pressure blast waves is the leading 
cause of combat-related injuries in the recent wars, compelling it to be labeled the signature 
12 
 
injury of the recent wars141. In addition to the cognitive and neurobehavioral symptoms 
experienced by soldiers following TBI, a number of somatosensory abnormalities have been 
documented, with visual and auditory disturbances being predominantly observed142-145. A 
study on soldiers injured in OIF found the majority of eye injuries to be the result of blast 
exposure146. Lew et al147 reported the occurrence of visual problems in 75% of the military 
patients at the Polytrauma Network Site, even though the majority of patients had near-
normal corrected visual acuity and visual fields. Patients at the Polytrauma Rehabilitation 
Center, a population with multiple, life threatening injuries, sustained higher rates of visual 
impairment and visual dysfunction148,149. A recent study by Brahm et al150 found 33% of all 
returning veterans to have some form of visual dysfunction primarily due to blast exposure; 
although visual acuity was near normal in most patients, visual field deficits and self-reported 
symptoms were increased among blast-injured soldiers. Commonly reported visual 
symptoms include diplopia, fixation instability, nystagmus, and blurred vision; in addition, 
abnormal vestibular ocular reflex, convergence insufficiencies, corneal injury, and 
oculomotor palsies have been observed clinically149.  
Blast wave physics 
Blast injuries are caused by the interaction of an explosive blast wave with different tissues. 
The injuries resulting from blast trauma have different clinical presentations compared to 
TBI mediated by flying projectiles, or by TBI induced by the deformation of the brain against 
the rigid surface of the skull151. It is commonly believed that blast-related brain injury may be 
due to transient pressure changes (initial 
overpressure followed by a negative 
phase creating a temporary vacuum) as 
the blast wave passes the subject151.  
Figure 2: Blast wave dynamics. Figure 
2A shows the idealized decay of a blast 
overpressure wave over time. Figure 2B 
(Source: David Mott, NRL Laboratory 
for Computational Physics and Fluid 
Dynamics152) shows the simulated effect of blast following the detonation of 1.5 kg C4 
Peak overpressure
Pr
es
su
re
Negative overpressure
Time
Black = 1 atm pressure
Red > 3.5 atm pressure
A. Idealized Friedlander waveform of blast B. Impact of blast wave
Atmospheric pressure
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explosives from a distance of 3 meters. Rapid variation in pressure and the amplification of 
pressure in the space between the helmet and head can be observed.  
Blast waves are created by the near instantaneous conversion of a solid/liquid explosive to a 
gas that occupies the same physical space. This gas promptly expands outwards, leading to 
an immediate increase in pressure, which rapidly dissipates over distance and time153. 
Following dissipation of the blast wave, a negative pressure phase develops as a result of the 
displaced air. This explanation however represents an idealized free-field blast wave; the 
non-linear dynamics of blast wave physics can be influenced by environmental conditions, 
and the blast wave can be amplified by interactions with blast-reflective surfaces154. Three 
major factors affect the likelihood of sustaining injuries as a result of blast exposure155. The 
medium in which the blast propagates determines the rapidity of expansion; for instance, due 
to the non-compressibility of water, an explosion in water generates a blast wave that 
propagates quicker than a blast wave in air, with minimal dissipation. The distance of the 
person from the blast epicenter also determines the peak overpressure exposure, since the 
blast wave dissipates over longer distances. The third factor is the location of the blast wave; 
an explosion within a closed space has greater potential for injury than one in an open space, 
due to reflection from walls and the containment of blast pressure within them. This also 
increases the risk for secondary and tertiary injuries, as a result, respectively, of penetrating 
projectiles and bodily impact against walls or other solid objects. Traditionally, blast wave 
has been predominantly thought to affect air-filled organs and viscera, such as the pulmonary 
system, gastrointestinal system, and auditory system156. However, this has been based on the 
premise that the blast peak overpressure is the only risk factor contributing to injury and does 
not explain brain injury157. Primary injury as result of blast wave can cause shear and stress 
forces that lead to edema, contusions, and diffuse axonal injury (DAI); ultimately, these 
shearing forces can damage cell bodies, axons, and vasculature in the brain and other 
organs151,158. A study of stress forces from explosions observed that the blast wave was 
capable of propagating directly to the brain; further, the equivalent of 0.324 kg TNT 
explosion at a distance of 0.6 m from epicenter was predicted capable of inducing brain 
injury comparable to those observed with sport concussions and mTBI154. These suggest a 
role for the blast wave itself contributing to CNS pathology. 
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Blast injury pathology 
Since it is difficult to delineate the effect of blast wave from confounding factors, very few 
clinical studies explicitly describe the pathology associated with blast exposure151. A patient, 
exposed to blast overpressure as a result of steam boiler explosion, had normal vital signs and 
no signs of blunt or penetrating wounds to the head and neck at admission; CT head scans 
revealed mild cerebral edema and diffuse hemorrhage, and he succumbed to his injuries post-
operatively159. A more recent event involved a soldier in Iraq, exposed to an explosive blast 
wave directly from her left side160. She was also in the vicinity of multiple blast events over 
the next 2 hours; it is notable that the patient remained conscious throughout. Three months 
after injury, MRI and DTI revealed abnormalities primarily in the auditory and cerebellar 
pathways; she also experienced persistent PCS. These case reports have been supported by 
recent experimental studies conducted with animal models of blast injury. Animals exposed 
to blast waves originating from a shock tube have been extensively studied161-163. The 
predominantly observed CNS pathology is diffuse axonal injury, and long axonal tracts 
appear to be the most susceptible to injury164-166. In particular, these studies reported 
degeneration localized to cerebellar, corticospinal, and optic tracts. Further evidence for 
neuronal injury, including expanded perineuronal spaces, cytoplasmic vacuoles, myelin 
deformation, and axoplasmic shrinkage, were observed in the hippocampus and brainstem 
reticular formation following blast injury161,167. Another factor that could influence DAI is 
increase in pressure within the cranial cavity. Increased intracranial pressure following 
exposure to blast wave has been reported experimentally and could potentiate the shearing 
effects of the shockwave itself168,169. Similar effects have been observed along the visual 
pathway. In one study, rats exposed to blast overpressure of 129-173 kPa had extensive 
degeneration of the primary visual pathway; axon degeneration was localized to the optic 
nerve, optic tracts, lateral geniculate body, and superior colliculus170. A recent study using 
the fluid percussion model of TBI has demonstrated the prechiasmatic region of the optic 
nerve is susceptible to traumatic axonal injury171. In this model, swollen optic nerve axons 
and disconnection of proximal and distal axonal segments were observed as early as 1-3 
hours post injury; a resultant dieback of the segments, reminiscent of Wallerian degeneration, 
occurred within 48 hours of injury. The proximal segment in particular demonstrated 
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significant swelling early after injury and rapidly transitioned to a thinned and shrunken 
appendage. The effect of trauma due to shearing against the bony canal surrounding the optic 
nerve could be an important factor mediating such dieback. Axonal injury can be 
accompanied by mitochondrial degeneration, leading to the activation of apoptotic 
mechanisms, and eventually, to neuronal death172. It has also been observed that in addition 
to neurons, oligodendrocytes and astrocytes are also susceptible to apoptotic death following 
TBI, in a region-specific manner173.  
Imaging and diagnosis 
Unlike the more severe forms of TBI with loss of consciousness, mTBI is difficult to 
diagnose due to subtle neurological symptoms and a lack of overt evidence of trauma. 
Currently, screening for mTBI in the theatre of war is predominantly by means of a self-
reported questionnaire—the brief traumatic brain injury screen (BTBIS)174—which might be 
followed by a neurocognitive assessment such as the Military Acute Concussion Evaluation 
(MACE)175. Another such assessment is the Automated Neuropsychological Assessment 
Metric (ANAM), which is used to monitor cognitive function of soldiers before deployment 
and following injury. However, these tests are more predictive of moderate-severe TBI176. 
Since mTBI is largely characterized by DAI, the study of white matter tracts by DTI is 
currently the most effective method to study structural integrity177. DTI has been employed 
widely to study soldiers with blast injury147,160,178, and it has been shown to be predictive of 
clinical outcome in patients with severe TBI179. However, in one study, no significant 
differences were observed using this technique in soldiers with milder injuries, although they 
revealed worse PCS and post-traumatic stress disorder (PTSD) scores compared to control 
subjects180.  
In addition to structural imaging, a number of functional changes have been documented 
using electrophysiological techniques. Evoked potentials (EP) and event-related potentials 
(ERP) have been widely utilized in the assessment of TBI and for the prediction of 
outcome181. Somatosensory EP (SEP), used to assess peripheral nerves, the spinal cord and 
somatosensory cortex pathways, has been reported to be the best overall predictor of outcome 
from severe TBI182. Median nerve SEP has been observed to predict negative outcome from 
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severe TBI or coma with high certainty183,184. However, SEP conducted in patients with 
milder injuries reveal no discernible difference compared to age-matched controls185. Pupil 
response to light has also been extensively used in TBI assessment. Pupillary responses have 
been reported to be the strongest predictor for awakening from coma186 and to have highest 
sensitivity for the prediction of a favorable outcome182. Further, a recent meta-analysis of 
8721 patients from the IMPACT database with moderate-severe TBI also found a strong 
correlation between unreactive pupils and negative outcome187.  
Of greater relevance to all severity levels of TBI are the long latency responses (LLR), a 
form of auditory ERP. This involves the presentation of auditory stimuli of constant 
frequency over the majority of the testing protocol; frequencies of different stimuli are 
interspersed with these tones at short intervals (an oddball paradigm)181. This elicits a P300 
response, generated from the frontal cortex, reticulothalamus, and the medial septal area, in 
normal subjects and is useful in cognitive assessments. A recent study of the P300 
amplitudes on athletes subject to multiple concussions revealed reduced amplitudes 
compared to controls188; although these athletes functioned normally, the persisting 
electrophysiological deficits could suggest susceptibility to further concussions. Further, a 
significant correlation between the P300 latency and fractional anisotropy from DTI has been 
reported in a study conducted on 11 patients with mild to moderate TBI177. Contingent 
negative variation (CNV), another ERP paradigm that tests attention, has been used to assess 
TBI patients; a study on 20 patients with mild TBI found abnormalities in the CNV when 
compared to control subjects189.  
Visual ERP (VERP) are valuable indicators of visual pathway integrity and cognitive 
function. In a VERP study on 17 patients with mild TBI190, compared to control subjects, 
TBI patients presented with deficits in complex visual integrative tests and significantly 
delayed latencies in texture segregation paradigms. An interesting observation in the study 
was that TBI patients with electrophysiological abnormalities were at greater risk of a 
negative vocational outcome, when compared to TBI patients with normal electrophysiology. 
Several studies have also documented reduced amplitude and delayed latency of the visual 
P300 component in patients with mild-moderate TBI189,191,192. One study also found a 
positive correlation between higher concussive episodes and longer P300 latency192. Many 
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paradigms that test visual tracking abilities of patients have proven useful in assessment of 
mTBI. One study of visual tracking abilities in 17 mTBI patients found a significant 
correlation between errors in gaze positioning and fractional anisotropy from DTI193. 
Recently, the King-Devick test, another measure of visual tracking ability, has been applied 
toward the rapid assessment of sport-related concussion194. Combination of structural 
imaging and representative functional measures might prove more useful in diagnosis. 
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Abstract 
Objective: To perform in vivo analysis of retinal functional and structural parameters in 
healthy mouse eyes. 
Animal Studied: Adult C57BL/6 male mice (n=37) 
Procedures: Retinal function was evaluated using pattern electroretinography (pERG) and the 
chromatic pupil light reflex (cPLR). Structural properties of the retina and nerve fiber layer 
(NFL) were evaluated using spectral-domain optical coherence tomography (SD-OCT). 
Results: The average pERG amplitudes were found to be 11.2 ± 0.7 µV (P50-N95, mean ± 
SEM), with an implicit time for P50-N95 interval of 90.4 ± 5.4 ms. Total retinal thickness 
was 229.5 ± 1.7 µm (mean ± SEM) in the area centralis region. The thickness of the retinal 
nerve fiber layer (mean ± SEM) using a circular peripapillary retinal scan centered on the 
optic nerve was 46.7 ± 0.9 µm (temporal), 46.1 ± 0.9 µm (superior), 45.8 ± 0.9 µm (nasal) 
and 48.4 ± 1 µm (inferior). The baseline pupil diameter was 2.1 ± 0.05 mm in darkness, and 
1.1 ± 0.05 mm and 0.56 ± 0.03 mm after stimulation with red (630 nm, luminance 200 
kcd/m2) or blue (480 nm, luminance 200 kcd/m2) light illumination, respectively.  
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Conclusions: Pattern electroretinography, cPLR and SD-OCT analysis are reproducible 
techniques, which can provide important information about retinal and optic nerve function 
and structure in mice.  
Introduction 
Non-invasive functional and structural assays such as electroretinography (ERG) and optical 
coherence tomography (OCT) can be utilized in animal models to obtain objective 
information regarding the status of the retina and optic nerve in vivo 195-197. These techniques 
allow repeated analysis without the need to euthanize the animal, and can be effectively used 
for longitudinal evaluation of disease progression or treatment efficacy. The function of 
retinal ganglion cells (RGCs) in rodents can be measured by recording the amplitude and 
latency of the pattern evoked electroretinogram (pERG)36,198-205. The pERG response is a 
result of RGCs depolarization30,206 with minimal glial cell contributions207,  which can be 
abolished by optic nerve transection31,32 or pharmacological blockade targeting RGC action 
potential activity30. Considering that the electrical response originates from RGCs, pERG has 
been used to evaluate RGC damage associated with glaucoma and ocular hypertension in 
human patients208-210 and in different animal models33-35.  
The chromatic pupil light response (cPLR) analysis is a relatively new diagnostic technique, 
which may provide information about the quality of rod-cone activity, rod-cone mediated 
electrical signal transmission to RGCs and characteristics of an intrinsically photosensitive 
subpopulation of RGCs (ipRGCs) containing the pigment melanopsin38,211-216. Recent 
reviews have excellently described the anatomy of ipRGCs and have summarized their role 
in mediating various functional properties217-220. Stimulation of the retina with red (630 nm) 
light activates strictly rod-cone mediated pupil light response, without activation of 
melanopsin mediated responses211.  The degree of contribution of rods vs. cones depends on 
the state of retinal adaptation, the spectral sensitivity of the photoreceptors in the species 
being studied and the brightness of the light. The rod-cone mediated pupil response requires 
six components: 1. normal functioning rods and cones and their respective neurons in the 
inner nuclear layer; 2. functional and well-organized dendritic arborization of ipRGCs to 
allow for a rod-cone generated electrical response to be transmitted to the ipRGCs that results 
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in a generation of PLR responses; 3. functional axons of ipRGCs to transmit the electrical 
information to the pretectal brain regions mediating the PLR and photopic blink responses; 4. 
normal status of the pretectal olivary nucleus as a brain interneuron relay station for 
mediating the PLR to both Edinger-Westphal Nuclei; 5. intact pre and post ganglionic 
parasympathetic nerve pathway (oculomotor nerve) as an efferent pathway for mediation of 
PLR response; and 6. an intact iris sphincter as an effector organ.  Stimulation of the retina 
with bright blue (480 nm) light can activate both a rod-cone mediated pupil response and a 
pupil response that is elicited by activation of the melanopsin in ipRGCs38,40,197,221,222. 
However, the melanopsin activated pupil response is typically more sustained after light 
termination. 
Spectral-domain optical coherence tomography (SD-OCT) is a high-resolution imaging 
technique used for direct in vivo analysis of retina and optic nerve head structure223-225. 
Recent studies have demonstrated that OCT analysis of retinal thickness provides nearly 
identical values compared to analysis of the same retinal regions using position-matched 
histological analysis226.  Different OCT segmentation protocols allow for the measurement of 
total retina thickness, photoreceptor layer thickness and thickness of the retinal nerve fiber 
layer (RNFL) in different retinal quadrants227-231. Recent utilization of OCT technology in 
rodent models of eye diseases has provided an objective measure of retinal structure, which 
can be used to monitor the structural effects of disease progression or treatment response230-
234. 
The principal objective of this study was to perform a detailed characterization of RGC 
functional and structural parameters with the goal of establishing normative data for adult 
healthy C57BL/6 mice as a basis for further investigations by us and others on the 
experimental effects of retinal and optic nerve disorders and their treatment. In this study we 
used pERG and cPLR analyses to evaluate the retinal function, and particularly RGC 
function, while SD-OCT was used to provide structural information about the retina, 
photoreceptor layer and RNFL thickness.   
Materials and Methods 
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Animals 
All animal studies were conducted in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and had the approval of the Iowa State 
University and VA Medical Center-Iowa City Institutional Animal Care and Use 
Committees. A total of 37 adult healthy male C57BL/6 mice (8-12 weeks of age, unless 
otherwise specified) were used for the purpose of this study. 
Pattern electroretinography 
Pattern evoked electroretinography (pERG) was used to objectively measure the function of 
the retinal ganglion cells by recording the amplitude and latency of the pERG waveform. 
Mice (n=37) were anesthetized with 0.8 l/min O2, 0.4 l/min nitrous oxide and 3.5% 
halothane. After anesthesia induction the halothane concentration was decreased to 1.75% 
and mice were placed on a stainless steel recording table equipped with an internal 
circulating hot-water based warming system (maintained at 39 °C) to maintain body 
temperature. The mice were positioned 20 cm from the stimulus monitor with their body 
angle tilted at 45 degrees to provide direct exposure of the stimulus to the visual axis of the 
recorded eye. The pupil was then dilated using 1% tropicamide solution (Tropicamide; 
Falcon Pharmaceuticals, Fort Worth, TX, USA). Pattern ERG responses were evoked using 
alternating, reversing, black and white vertical stimuli delivered on a monitor (Fig. 1 A) with 
a Roland Consult ERG system (Roland Consult, Brandenburg, Germany).  To record the 
pERG response, commercially available mouse corneal gold ring electrodes were used (S&V 
Technologies AG, Germany). A reference needle electrode was placed at the base of the 
head, and a ground electrode was placed at the base of the tail to complete the circuit. Each 
animal was placed at the same fixed position in front of the monitor to prevent recording 
variability due to animal placement. Stimuli (9° radius visual angle subtended on full field 
pattern, 1 Hz temporal frequency, 0.05 cycles/deg spatial frequency, 97% contrast, 80 cd/m2 
monitor luminance, 200 averaged signals with cut off filter frequencies of 1-30 Hz) were 
delivered under photopic conditions, since slower stimulation rates in mesopic and scotopic 
conditions can elicit rod-mediated full field ERG responses, which can completely conceal 
the pERG response. Retinal pERG responses were evaluated by measuring the amplitudes 
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(N35-P50 and P50-N95) and respective implicit times (Fig. 2). Implicit times were calculated 
for N35, P50 and N95 markers, in addition to the implicit time for N35-P50 and P50-N95 
components. Seven mice were repeatedly recorded at 3, 11, and 15 months of age to 
determine whether aging has any effect on pERG amplitudes or implicit times. 
Chromatic pupillography 
Chromatic pupil light reflex (PLR) was characterized in mice (n = 8) using the A2000 
computerized pupillometer (Neuroptics, San Clemente, CA). The pupillometer consists of a 
sensitive pupil tracking software, which can be programmed to include various PLR 
recording routines and can provide the required red/blue light illumination. Red light of 630 
nm was used to elicit strictly rod-cone mediated PLR, since red light of 630 nm wavelength 
does not activate the intrinsic RGC photopigment melanopsin (Fig. 5). Blue light was used to 
elicit combined responses (rod-cone response + melanopsin intrinsic response).  The 
wavelength of light emitted by the diodes was 622 ± 7 nm for red light and 463 ± 13 nm for 
blue light. Red and blue light stimuli were matched and had illuminance of 1 (0 log units), 4 
(0.6 log units),16 (1.2 log units), 63 (1.8 log units), 251(2.4 log units) and 1000 (3 log units) 
lux. The maximum luminance measured at the position of the mouse eye using a photometer 
(J17LumaColor with luminance head model J1803; Tektronix, Wilsonville, OR) was 3700 
cd/m2 for the illuminance of 1000 lux.  The pupil was illuminated for a period of 500 
milliseconds.  All PLR testing routines were recorded in completely awake mouse without 
the use of general anesthetic or sedation. The mice were initially habituated to extensive 
handling with food rewards, in order for them to remain calm during recording. The 
experiments were then carried out under scotopic conditions with no background 
illumination from the pupillometer. Only the direct response of the pupil was observed 
following illumination with red/blue light stimulus. The pupil response was expressed as the 
percent contraction of the pupil from baseline. 
To evaluate pupil responses with much higher light intensity, the PLR analysis was 
performed using a Melan-100 instrument (BioMed Vision Technologies, Ames, IA,). Similar 
as before, mice (n=11) were awake during the recording session and were held still using 
minimal manual restraint. Recording sessions in most animals lasted less than one minute. 
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The Melan-100 has two powerful diode based light sources with very narrow wavelength 
bands (630 ± 5 nm for red light, luminance 200 kcd/m2; 475 ± 5 nm for the blue light, 
luminance 200 kcd/m2). Baseline pupil diameter measurements in mice were taken in 
darkness prior to illumination using an infrared video camera (Sony Handycam, Sony 
Corporation). Red light stimuli with two second duration were used to illuminate one eye of 
the mouse at a distance of 4 cm from the ocular surface and direct pupil responses were 
recorded from the illuminated eye with the digital infrared camera. Prior to performing 
illumination with the blue light, pupils were allowed to completely dilate to the baseline 
diameter. Captured digital movies of pupil responses were analyzed using Adobe Photoshop 
(v. 10.0.1, Adobe Systems, Inc.). Calibrated dot grid with dot sizes of 0.5, 1,1.5, 2 and 3 mm 
in diameter were recorded with a camera from the 4 cm distance to calculate the regression 
equation so calculation of absolute pupil diameters from the recorded images could be 
performed.  
Spectral domain optical coherence tomography  
Spectral domain optical coherence tomography analysis (SD-OCT) was performed on 
anesthetized mice (n=22) using a Spectralis SD-OCT (Heidelberg Engineering, Vista, CA) 
imaging system (Fig. 1 B), coupled with a 25D lens for mouse ocular imaging (Heidelberg 
Engineering, Vista, CA). Mice were anesthetized using 2.5% halothane and 100% oxygen 
mixture on a heating pad to maintain body temperature. Pupils were dilated using a 1% 
tropicamide solution. The cornea was moisturized with a saline solution, which was applied 
every 20-30 seconds. Circular scans around the optic nerve region were performed to 
quantify NFL thickness in the temporal, superior, nasal and inferior retinal quadrants.  
Circular scans were subsequently analyzed by including or excluding blood vessels from the 
RNFL thickness calculation, since blood vessels in rodents are almost completely embedded 
in the RNFL235 and are included in automated RNFL measurement routines by all 
commercially available systems. Linear scans were also performed in the superio-temporal 
region of the retina (area centralis) in order to evaluate total retinal thickness, thickness of 
the photoreceptor layer and the RNFL thickness. Total of 25 linear scan lines were positioned 
in the superio-temporal retina. The most superior linear scan line was positioned 2.5 – 3 mm 
superior/1.5 – 2 mm temporal to the optic nerve head. 
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Statistical analysis 
All statistical analyses were carried out using GraphPad Prism 5.0 (GraphPad software, San 
Diego, CA). Paired t-tests, one-way ANOVA with Bonferroni’s post test, or repeated 
measures ANOVA with Bonferroni’s post test analysis were used as described in the text.  
Differences between groups were considered statistically significant for p < 0.05. 
Results 
Pattern Electroretinography 
Average pERG amplitudes were 9 ± 0.6 µV (N35-P50, mean ± SEM) and 11.2 ± 0.7 µV 
(P50-N95, Fig. 3A). Repeated measurement of pERG amplitudes in the same mice (four 
different recording sessions with a 7 day time interval between sessions for the same animal) 
revealed no significant inter-session difference compared to initial baseline recordings 
(p=0.4, Repeated Measures ANOVA with Bonferroni post test analysis, Fig. 3 B). The intra-
animal variability across recording sessions was 1.9 ± 0.1 µV, with a 27.1 ± 2.7% coefficient 
of variation.  Additionally, comparison of pERG amplitudes from the right and left eye 
revealed no significant interocular variability for the N35-P50 (p = 0.5, Paired t-test) or P50-
N95 amplitudes (p = 0.1, Paired t-test). The pERG implicit times were: 29.3 ± 1.8 ms (N35), 
78.4 ± 3.5 ms (P50) and 168.9 ± 6.6 ms (N95), with durations of 49.2 ± 3.2 ms (N35-P50) 
and 90.4 ± 5.4 ms (P50-N95, Fig. 3 C, D). In order to observe the effect of aging on the 
pERG response, recordings were conducted at 3 months, 11 months and 15 months of age on 
the same animals (Fig. 4). The average N35-P50 amplitude was 4.3 ± 0.9 µV, 6.6 ± 1.1 µV, 
and 6.2 ± 1.4 µV at 3 months, 11 months, and 15 months of age, respectively (Fig 4A). The 
average P50-N95 amplitude was 8.7 ± 1.3 µV, 7.9 ± 0.5 µV, 7.9 ± 1 µV at 3 months, 11 
months, and 15 months of age, respectively (Fig. 4B). The average N35-P50 latency was 
42.1 ± 5.3 ms, 58.5 ± 13.2 ms, and 56.7 ± 9.3 ms at 3 months, 11 months, and 15 months of 
age, respectively (Fig 4C). The average P50-N95 latency was 86 ± 14.3 ms, 137.4 ± 18.1 ms, 
and 123.9 ± 14.4 ms at 3 months, 11 months, and 15 months of age, respectively (Fig 4D). 
No statistically significant difference was observed in both amplitudes and latencies at 
different ages (Repeated Measures ANOVA with Bonferroni post test analysis: N35-P50 
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amplitude, p = 0.3; P50-N95 amplitude, p = 0.8; N35-P50 latency, p = 0.5; and P50-N95 
latency, p = 0.1). 
Chromatic Pupillography 
The visual pigments present in the mouse retina (Fig. 5) have been previously characterized 
236-238, and their differential contribution to the pupil light reflex has been utilized to 
characterize the functional properties of different retinal neuronal cells 211. For red light 
stimulus the pupil constriction was 3.3 ± 0.4% of baseline size (0 log units), 6.6 ± 0.7% (0.6 
log units), 14 ± 1.2% (1.2 log units), 21.13 ± 1.8% (1.8 log units), 25.9 ± 1.1% (2.4 log 
units), and 31.6 ± 0.9% (3.0 log units), respectively (Fig 6). However, blue light stimuli 
resulted in significantly greater pupil constriction for all tested light intensities (Fig 6):  0 log 
units, 20.3 ± 1.8% (p < 0.0001, Paired t-test); 0.6 log units, 30.3 ± 1.5% (p < 0.0001, Paired 
t-test); 1.2 log units, 42.6 ± 1.7% (p < 0.0001, Paired t-test); 1.8 log units, 51 ± 2% (p = 
0.0001, Paired t-test); 2.4 log units, 60.6 ± 2.9% (p < 0.0001, Paired t-test); and 3.0 log units, 
64 ± 3% (p < 0.0001, Paired t-test).  
Pupil constriction in response to light of different wavelengths was also characterized with 
the Melan-100 instrument using higher light intensity (200 kcd/m2). Baseline pupil diameters 
calculated prior to illumination in dim light conditions were 2.1 ± 0.05 mm (Fig. 7 A, D).  
The pupil diameter after constriction in response to red (630 nm) light stimulation was 1.1 ± 
0.05 mm (Fig. 7 B, D). Stimulation with blue light induced significantly greater constriction 
of the pupil to a diameter of 0.56 ± 0.03 mm, compared to stimulation with red light (Fig. 7 
C, D; p < 0.001, Paired t-test). The pupil constricted by 44.3 ± 3.3% (mean ± SEM) of the 
baseline value with red light stimulus, and the pupil constricted by 71.8 ± 1.9% of the 
baseline value with blue light stimulus.  
Optical Coherence Tomography 
Spectral-domain OCT was used to non-invasively analyze the RNFL and total retinal 
thickness in vivo. SD-OCT analysis revealed a total retinal thickness of 229.5 ± 1.7 µm (Fig. 
8A, 9A; mean ± SEM) in the area centralis of healthy mouse eyes. The photoreceptor layer 
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thickness was 83.8 ± 0.7 µm, with RNFL thickness of 29 ± 0.5 µm in the region of the retina 
that corresponds to the area centralis (Fig. 8A, 9A). The thickness of the RNFL using 
circular scans and automated segmentation protocols was 46.7 ± 0.9 µm (temporal), 46.1 ± 
0.9 µm (superior), 45.8 ± 0.9 µm (nasal) and 48.4 ± 1 µm (inferior) (Fig. 8, 9). The thickness 
of the RNFL did not vary between quadrants (p = 0.1, ANOVA with Bonferroni’s post test). 
Analysis of RNFL thickness by excluding blood vessels thickness from the calculation was 
22.8 ± 0.6 µm (temporal), 24.4 ± 0.5 µm (superior), 24.3 ± 0.6 µm (nasal) and 23.6 ± 0.8 µm 
(inferior) (Fig. 8B, 9C). The thickness of the RNFL did not vary between quadrants (p = 0.2, 
ANOVA with Bonferroni’s post test). Exclusion of blood vessels from the analysis resulted 
in significantly decreased RNFL thickness for all tested quadrants when compared to values 
obtained with inclusion of blood vessels: temporal (p<0.0001, Paired t-test), superior 
(p<0.0001), nasal (p<0.0001) and inferior quadrant (p<0.0001).   
Discussion  
Repeated measurements of RGC structural and functional parameters are essential for 
following temporal disease progression or treatment effectiveness in different models of 
retina and optic nerve diseases.  In this study we have characterized the normative values for 
healthy adult C57BL/6 mice using pattern electroretinography, chromatic pupillography and 
optical coherence tomography.  
Pattern electroretinography has been successfully used in a rodent model of hereditary 
glaucoma (DBA/2J) to detect RGC deficits239. The baseline values reported for young 
DBA/2J mice prior to loss of RGCs were 8.15 ± 0.4 µV, which are similar to values obtained 
from adult healthy mice in our study. Repeatability is particularly important if pERG is to be 
used as a longitudinal tool to monitor RGC function for comparative purposes during disease 
progression or treatment effectiveness in the same animal. We have demonstrated that pERG 
recordings did not have significant intersession differences from baseline in our experimental 
conditions. The lateral eye position of rodents necessitates recording either one eye at a time 
or using two different stimulus monitors simultaneously; in our study, we have recorded one 
eye at a time using a single stimulus monitor, similar to previously published studies 239,240. 
The experimental setup that we used did not result in a significant interocular difference of 
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pERG amplitudes or implicit times between right and left eyes, providing an opportunity to 
effectively monitor temporal RGC function in each eye. Furthermore, we have demonstrated 
that the RGC function does not vary significantly as mice age from 3 to 15 months. The 
pERG amplitudes and latencies at 11 months and 15 months of age did not change 
significantly from earlier recordings on the same mice at 3 months of age.  
The PLR is an objective measure of retina and optic nerve function. The PLR has been used 
to monitor functional deficits caused by retina and optic nerve diseases in laboratory 
animals195,196,241-243. Recently, chromatic PLR analysis has been used in clinical settings in 
humans244-246 and dogs211 to monitor the rod-cone mediated and melanopsin mediated PLR 
responses. White light has been traditionally used for PLR analysis both clinically and 
experimentally. Since white light is a mixture of wavelengths of the visible spectrum 
(including red and blue), differentiation of rod-cone and ipRGC-mediated PLR activity 
cannot effectively be achieved with white light stimuli. As previously shown in healthy 
dogs211, we have demonstrated that red light causes significantly less pupil constriction when 
compared to the blue light stimulation in healthy mouse eyes. Since blue light of 480 nm 
wavelength can activate all visual pigments in the mouse retina except the UV cone opsin, 
this type of stimulus provides the most robust activation of the PLR response. Based on the 
spectral properties of photosensitive pigments in mice, the red light (630 nm) can activate 
rhodopsin and M-cones, but not UV cones and the intrinsic photosensitive pigment 
melanopsin247,248, which provides an opportunity for the specific evaluation of rod-cone 
mediated functional properties by measuring the red light mediated PLR responses. It has 
been previously shown that the ipRGCs project to midbrain structures and can mediate PLR 
activity and photopic blink response even in the complete absence of rod-cone input249. 
Furthermore, a subset of ipRGCs projects to the region of the lateral geniculate nucleus 
(LGN) and can mediate irradiance dependent firing rates of almost 40% of neurons in the 
LGN250. While the small number of ipRGCs in the mammalian retina does not suggest a 
primary role of ipRGCs in visual processing, a recent study has demonstrated that rod and 
cone deficient mice can still effectively recognize pattern gratings in a visual maze test using 
only melanopsin-mediated light processing 251. Because the peak of melanopsin activation 
occurs near 480 nm (blue light)247, and melanopsin cannot be activated by red light (630 nm), 
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red light based routines for evaluation of PLR can be effectively used to evaluate the status of 
RGC dendritic synaptic connections in cases where the rod and cone electrical activity is 
completely normal. A defect in the red light pupil response (rod-cone mediated signaling to 
ipRGCs) coupled with a normal blue light pupil response (suggestive of the normal ipRGC 
function) and normal scotopic and photopic ERG responses could be potentially indicative of 
a dysfunction in the RGC dendritic network. Chromatic PLR evaluation could be used for 
monitoring early retinal functional deficits in transgenic mouse models, or as an objective 
test for evaluation of the retina and RGC function as a result of experimental therapeutic 
treatments. Defects of the pupillary light reflex after illumination with the red and blue light 
in the presence of normal scotopic and photopic ERG responses would indicate a problem 
with the ipRGC soma, axons or higher processing areas of the brain (pretectum) or more 
distal nerve or iris muscle deficits. Considering that rod-cone mediated pupil input has to 
converge to ipRGCs which have large diameter axons, compressive optic nerve lesions and 
inflammatory optic nerve conditions theoretically could selectively impair this cell 
population resulting in decreased or absent PLR response while still sparing majority (or 
some) of smaller diameter RGCs resulting in the presence of some functional vision 
(Grozdanic et al, ACVO Abstract, San Antonio, TX, 2006). However, a majority of clinical 
and experimental conditions that we have evaluated during the last 5 years using chromatic 
PLR testing in different animal species are frequently characterized by an intact ipRGC 
mediated response to blue light illumination - even in cases where complete blindness based 
on visual behavior is already present211.  
While pERG and PLR are functional monitoring techniques that can detect functional deficits 
before any structural retina or retinal nerve fiber layer (RNFL) changes occur, observation of 
structural retina parameters remains a very frequently utilized measure of therapeutic 
outcome in animal models of ophthalmic diseases. Spectral domain OCT is a tool that has 
been extensively used to diagnose and monitor diseases of the eye and retina including 
glaucoma6, retinitis pigmentosa7, and macular degeneration8. Measurements of macular 
volume252 and RNFL thickness253 using OCT have also been used to estimate overall 
neuronal loss in patients with multiple sclerosis, while one recent clinical study has 
demonstrated inner retina thinning in patients with idiopathic Parkinson’s disease254. 
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Considering the diversity of transgenic mouse models for ophthalmic and neurodegenerative 
diseases, it is likely that SD-OCT imaging will become a useful technique for evaluation of 
structural optic nerve properties in many different animal disease models. Similar to recently 
published results with the use of adaptive optics and 78D lens11, we have demonstrated that 
by using a 25-diopter lens, high quality OCT scans of the mouse retina can be obtained. It 
has been previously demonstrated that automated RNFL analysis routines overestimate 
RNFL thickness due to the inclusion of blood vessels in the RNFL thickness calculation255. 
We have also demonstrated a substantial increase in the RNFL thickness when blood vessels 
were included in the calculation. Since blood vessels are predominately embedded within the 
RNFL in a majority of animal species, a subtle increase or decrease in RNFL thickness could 
be potentially masked by change in the blood vessel diameter due to the overwhelming 
contribution of the blood vessels to the RNFL thickness calculations with conventional SD-
OCT software.   
There are several limitations which can decrease the effective use of the cPLR and SD-OCT 
responses for evaluation of the retina and optic nerve status. Mice with severe forms of iris 
atrophy or prominent intraocular inflammation can have significantly attenuated PLR 
responses, while the application of topical ocular medications with miotic or mydriatic action 
can also have a significant effect on the resting pupil diameter and overall pupil motility.  
Furthermore, CNS and peripheral nerve abnormalities, which can be frequently present in 
different transgenic mouse models affecting any of the subthalamic PLR centers or efferent 
PLR pathway components, can have significant effects on the quality of PLR responses, 
which may be a potentially limiting factor during cPLR testing routines. Similarly, 
limitations in pupil dilatation may have the potential effect on the quality of SD-OCT 
imaging. Presently, we are developing automated OCT segmentation software routines that 
are specific for mouse retina which are likely to improve further the application of OCT in 
mouse species. 
Detailed in vivo analysis of functional and structural retina and RGC parameters can provide 
a significant advantage during evaluation of transgenic animal models of human ocular and 
neurodegenerative diseases. Introduction of these techniques may result in a significant 
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acceleration developing new therapeutic strategies, since all observed techniques are 
commonly utilized in human patients, which may allow for a rapid translation of animal 
study results to human patient population. Considering that the mouse is probably the most 
frequent experimental animal species encountered by veterinary ophthalmologists during 
toxicity and clinical safety/efficacy studies, the availability of normative pERG, chromatic 
PLR and OCT data may provide useful information for more specific evaluation of 
functional and structural retinal properties in this particular animal species.  
Acknowledgements  
This work was supported by the Department of Veterans Affairs Center for Prevention and 
Treatment of Vision Loss (CPTVL), VA RRD Grants C3919R and C4702R, Iowa Center for 
Advanced Neurotoxicology (ICAN) and the NIH (1R01EY019294). 
Figures 
Figure 1 
 
Figure 2 
 
31 
 
Figure 3 
 
Figure 4 
 
 
32 
 
Figure 5 
 
Figure 6 
 
33 
 
Figure 7 
 
Figure 8 
 
34 
 
Figure 9
 
Figure Legends 
Figure 1: A) Pattern ERG recording in mice.  The mouse is positioned on a heated table and 
placed 20 cm from the stimulating screen. The position of the table and eye orientation is 
carefully controlled to provide consistent placement of the animal eye in front of the 
stimulating monitor. B) OCT recording in mice.  A special 25D lens is attached to the SD-
OCT Spectralis system for performing OCT imaging in mouse eyes. Anesthetized mice are 
kept warm by placement on a heating pad for the duration of the recording. 
Figure 2: Representative mouse pERG tracing. Amplitudes are calculated for N35-P50 and 
P50-N95 intervals. It is considered that P50-N95 amplitude represents electrical activity of 
the retinal ganglion cell body and dendritic tree as a result of cell membrane depolarization. 
Figure 3: Pattern ERG responses in healthy mice. A) Average pERG N35-P50 and P50-N95 
amplitudes. B) Repeated measurement of pERG amplitude (amplitudes are presented as a 
ratio against the very first recording) in the same mice did not reveal significant differences 
(p > 0.1, Repeated Measures ANOVA). C, D) Analysis of implicit times showed higher 
implicit time for specific components of pERG waveform in mice when compared to 
previously reported values in humans and dogs.  
Figure 4: Effect of age on pattern ERG responses in healthy mice.  A, B, C, D) There was no 
statistically significant difference in amplitudes (A, N35-P50 amplitude; B, P50-N95 
amplitude) and latencies (C, N35-P50 latency; D, P50-N95 latency) between 3, 11, and 15 
month old mice.  
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Figure 5: Spectral properties of visual pigments in mice. Mouse retina has following visual 
pigments: rod opsin (λmax at 498 nm), and two cone opsins (the UV cones with λmax at 360 
nm and the green cones with λmax at 508 nm). In addition to these photoreceptor pigments, a 
specific subset of ganglion cells (intrinsically photosensitive retinal ganglion cells, ipRGC) 
contains the photopigment melanopsin, which has λmax at 479 nm. Therefore, when red light 
of 620-630 nm wavelength is used as a stimulus, only the green cones and rods are activated. 
However, when blue light of wavelength 480 nm is directed on the retina, all retinal 
photopigments (with exception of UV cones) are activated. This difference in spectral 
properties can be utilized to identify functional deficits in specific cell types within the retina 
(Figure modified from Lucas, Douglas et al. 2001).  
Figure 6: Chromatic pupil light reflex evaluation in mice using A-2000. A) Luminance of red 
and blue lights for different illumination parameters (0, 0.6, 1.2, 1.8, 2.4, 3 log (lux) units) 
was measured using a photometer. B) Significantly higher pupil constriction was observed 
following blue light stimulus when compared to the red light stimulus for all tested light 
intensities (* p<0.0001). 
Figure 7: Chromatic pupil light reflex in mice using Melan-100. Representative images of 
pupil A) baseline diameter, and after stimulation with B) red (630 nm, 200 kcd/m2) or C) 
blue (480 nm, 200 kcd/m2) light. D) Pupil diameter variation from baseline following 
stimulation with red and blue light.  
Figure 8: Optical coherence tomography. A) Retina linear scans were used to evaluate the 
total retinal thickness and to calculate the thickness of the outer nuclear layer (photoreceptor 
bodies) and the RNFL in the superior retina (area centralis region). B) Peripapillary scans 
were used to determine the RNFL thickness in the temporal, superior, nasal and inferior 
retinal quadrants. Area of blood vessels is demarcated with dashed circles. C) Fundus image 
of a mouse eye demonstrating area of the circular scan (grey circle). Abbreviations: RNFL –
retinal nerve fiber layer; IPL– inner plexiform layer; INL – inner nuclear layer; ONL – outer 
nuclear layer.  
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Figure 9: SD-OCT retinal thickness parameters in healthy mice. A) Total retinal thickness, 
photoreceptor layer thickness, and RNFL thickness at the area centralis region, measured 
using SD-OCT. B) Circular scan analysis of the RNFL thickness with inclusion of blood 
vessels in the RNFL profile - there was no significant difference in RNFL thickness in 
different quadrants. C) Circular scan analysis of the RNFL thickness without inclusion of 
blood vessels in the RNFL profile showed significantly smaller thickness compared to values 
obtained by calculations performed by standard software routines (with inclusion of blood 
vessels) presented in image B. ONL – outer nuclear layer, AC – area centralis, b.v. – blood 
vessel. 
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CHAPTER III. PROTEIN KINASE C DELTA MEDIATES RETINAL 
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A manuscript prepared for submission to Investigative Ophthalmology and Visual Sciences, 
2012 
K. Mohan, M.M. Harper, A. Ghosh, V. Ananthram, A.G Kanthasamy, A. Kanthasamy, R.H. 
Kardon, S.D. Grozdanic 
Abstract 
Purpose: To characterize the functional and structural changes of the retina in a rodent model 
of Parkinson’s disease (PD) using electroretinography (ERG), optical coherence tomography 
(OCT), and histology analysis and study the role of protein kinase C delta (PKCδ) in 
mediating these changes. 
Methods: Pattern evoked electroretinography (pERG) and full field ERG were used to 
objectively evaluate retinal ganglion cell and total retinal function. Baseline amplitudes and 
latency were evaluated in wild type and PKCδ-/- mice prior and after induction of PD 
phenotype. A PD phenotype was created by injection of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). OCT and histology analysis were used to evaluate retinal 
morphological changes.  
Results: Analysis of the acute MPTP model of PD in wild-type mice revealed a significant 
decrease in the P50-N95 amplitude (4.42±0.4 µV) at 48 h post MPTP treatment when 
compared to baseline recordings (P50-N95 amplitude, 8.78±0.5 µV; p<0.0001, Paired t-test). 
Full field ERG analysis showed significant deficits in oscillatory potentials, however the 
maximum scotopic a- and b-wave amplitudes were not significantly reduced. A significant 
increase in the retinal nerve fiber layer thickness was observed by OCT analysis at 4 months 
after acute MPTP treatment. The P50-N95 amplitude (7.77±0.6 µV) in the MPTP-treated 
PKCδ-/- mice did not differ significantly from baseline (pre MPTP amplitudes) P50-N95 
amplitudes (9.505±0.69 µV).  
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Conclusion: Visual dysfunction in the mouse MPTP model of PD is characterized by a 
significant loss of retinal ganglion cell function and structure, which may be partially 
mediated by PKCδ. 
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with clinical symptoms 
of tremor, rigidity, and akinesia256.  A pathological hallmark of PD is the selective loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) with a concurrent 
reduction of dopamine in the striatum62. Although PD is predominantly associated with 
movement disorders, different types of visual deficits have been reported in human patients. 
A loss in visual contrast sensitivity112 and spatiotemporal contrast sensitivity113, 114 has been 
reported among PD patients. Additionally, visual acuity has been reported to decline 
progressively over time with disease progression in a small group of PD patients111. Delays 
in visual-evoked potentials were initially reported in PD patients by Bodis-Wollner and 
Yahr257. The full field electroretinogram (ERG) amplitudes have also been shown to be 
decreased in PD patients258, while dopamine deficiency has been found to influence the 
multifocal ERG amplitudes259. Pattern-evoked electroretinography (pERG) is a sensitive, 
non-invasive tool for the measurement of retinal ganglion cell (RGC) function. Several 
studies have demonstrated a decrease in pERG amplitudes associated with early and 
advanced PD in human patients260, 261, 262, in addition to alterations in the amplitudes and 
latencies of the pERG130, 262. It has been hypothesized that visual dysfunction in PD may be 
caused by disruption of the retinal dopaminergic neuronal system263, 264. A recent 
morphological study of the retina in PD patients using optical coherence tomography showed 
significant nerve fiber layer (NFL) loss even prior to the development of any visual 
deficits265, further enhancing the need to more critically address functional and structural 
retina changes in PD patients. 
The principal purpose of this study was to evaluate retinal changes in a rodent model of PD 
that develops clinical symptoms of PD as a result of exposure to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP).  MPTP was identified to cause a PD-like phenotype in humans63, 
and has been frequently used as a neurotoxin capable of destroying nigrostriatal 
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dopaminergic neurons and inducing PD phenotypes in different animal species62. Optical 
coherence tomography, full field electroretinography, pattern electroretinography and 
histology analysis were used to perform detailed retinal functional and structural analysis in 
this animal model with an ultimate goal of establishing a better understanding of the possible 
pathological effects of PD on the retina and optic nerve. Several recent studies have 
implicated protein kinase C delta in development of PD pathology266-268.  We have evaluated 
the role of PKCδ the development of retinal abnormalities in the mouse model of MPTP 
induced PD. 
Materials and Methods 
Animals and MPTP treatment 
A total of forty C57Bl/6 mice and eight PKCδ-/- mice were housed under standard conditions: 
constant temperature (22 ± 1°C), humidity (relative, 30%), and a 12 h light/dark cycle with 
access to food and water, ad libitum. PKC -/- animals were obtained from the animal breeding 
facility of Dr. Anumantha Kanthasamy’s laboratory (Department of Biomedical Sciences, 
Iowa State University, Ames, Iowa). All animals were evaluated by pattern 
electroretinography, full-field electroretinography, and optical coherence tomography to rule 
out the presence of ocular diseases before inclusion in the study. For induction of acute 
MPTP toxicity mice received four intraperitoneal injections of MPTP-HCl (18 mg/kg of free 
base; Sigma-Aldrich) dissolved in saline at 2 h intervals as previously reported 269. Control 
animals received only saline injections. Mice were euthanized and prepared for analysis 48-
72 h post-treatment. The sub-chronic MPTP treatment involved one dose of MPTP (30 
mg/kg), repeated daily over 5 days. Mice were sacrificed 16 days after the first injection. All 
animal studies were conducted in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and were approved by the Iowa State University 
Institutional Animal Care and Use Committee.  
Pattern electroretinography 
Pattern evoked electroretinography (pERG) was used to objectively measure the function of 
RGCs by recording the amplitudes and latency of N35-P50 and P50-N95 pERG waveforms. 
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Mice (Acute MPTP, wild-type n = 22, PKCδ-/- n = 8; Sub-chronic MPTP, wild-type n = 10) 
were anesthetized with a mixture of 75% oxygen, 25% nitrous oxide and 3.5% halothane. 
After induction, mice were placed on a stainless steel recording table equipped with a hot-
water based warming platform to maintain body temperature and the halothane concentration 
was decreased to 1.75%. Mice were positioned 20 cm from the stimulus monitor with their 
head angle tilted at 45 degrees to provide direct exposure of the pattern stimulus to the visual 
axis of the recorded eye. Pattern ERG responses were evoked using alternating, reversing, 
black and white vertical stimuli delivered on a CRT monitor with a Roland Consult ERG 
system (Roland Consult, Brandenburg, Germany).  Each animal was placed at the same fixed 
position in front of the monitor to prevent recording variability due to animal placement. 
Stimuli (9° full field pattern, 1 Hz frequency, 200 averaged signals with cut off filter 
frequencies of 1-30 Hz) were delivered in photopic conditions, since slow stimulation speed 
in mesopic and scotopic conditions can elicit rod-mediated full field ERG responses, which 
can completely conceal the pERG responses in rodents. Visually evoked responses were 
evaluated by measuring the amplitudes (N35-P50 and P50-N95) and corresponding implicit 
times (latency) of the waveform.  
Spectral domain optical coherence tomography  
Spectral domain optical coherence tomography (SD-OCT) analysis was performed on 
anesthetized mice using Spectralis SD-OCT (Heidelberg Engineering, Vista, CA) imaging 
system, coupled with a 25D lens for mouse ocular imaging (Heidelberg Engineering, Vista, 
CA). Mice (n = 8) were anesthetized using 2.5% halothane and 100% oxygen mixture on a 
heating pad to maintain body temperature. Pupils were dilated using a 1% tropicamide 
solution. The cornea was moisturized with a saline solution, which was applied every 20-30 
seconds. Linear scans were collected from the superior-temporal region of the retina, which 
corresponds to the macular region in primates in order to evaluate the RNFL thickness. 
Full-field electroretinography 
Mice (n = 4) were dark adapted for 12 h prior to recordings. Mice were anesthetized with a 
mixture of 75% oxygen, 25% nitrous oxide and 3.5% halothane, while anesthesia was 
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maintained using a mixture of 75% oxygen, 25% nitrous oxide and 1.75% halothane. After 
induction, mice were placed on a stainless steel recording table equipped with a hot-water 
based warming platform to maintain body temperature. The mice were positioned inside a 
Ganzfeld stimulating globe. The luminance in all globe quadrants was 1600 ± 200 cd/m2.  A 
Roland Consult (Brandenburg, Germany) ERG system was used to deliver stimuli triggered 
output to the flash stimulator and to collect signals from both eyes using custom made mouse 
gold ring lens electrodes (Roland Consult, Brandenburg, Germany).  The maximum scotopic 
rod-cone response was recorded, with the stimulus delivered at 0.07 Hz frequency (low-cut 
amplifier frequency, 1 Hz; high-cut amplifier frequency, 300 Hz; 8 averaged responses per 
recording session). Oscillatory potentials (OPs) were recorded by delivering light stimuli at a 
0.07 Hz frequency (low-cut amplifier frequency, 200 Hz; high-cut amplifier frequency, 500 
Hz;]; n = 8 stimuli were averaged).  The photopic flicker response was recorded using from 
light adapted animals by delivering light stimuli at a 20 Hz frequency (low-cut amplifier 
frequency, 1 Hz; high-cut amplifier frequency, 300 Hz; n = 50 stimuli were averaged). 
HPLC analysis 
The striatal and ocular dopamine (DA) levels were quantified using high-performance liquid 
chromatography (HPLC) with electrochemical detection. Samples were prepared and 
quantified as described previously 270, 271. Briefly, 48 h after MPTP injection, control (n = 4) 
and treated mice (n = 10) were sacrificed, striata and eyes were collected and stored at -80°C.  
Dopamine from tissues was extracted in 0.1 M perchloric acid solutions containing 0.05% 
Na2EDTA and 0.1% Na2S2O5). Isoproterenol was used as an internal standard. Extracts were 
filtered in 0.22 µm spin tubes and 20 µl of the sample was loaded for analysis.  Dopamine 
was separated isocratically in a reversed-phase C-18 column using a flow rate of 0.7 ml/min. 
An HPLC system (ESA Inc., Bedford, MA, USA) with an automatic sampler equipped with a 
refrigerated temperature control (model 542; ESA Inc.) was used for these experiments. The 
electrochemical detection system consisted of a Coulochem model 5100A with a 
microanalysis cell (model 5014A) and a guard cell (model 5020) (ESA Inc.). Standard stock 
solutions of catecholamines (1 mg/ml) were prepared in perchloric acid solution and further 
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diluted to a final working concentration of 50 pg/µl prior to injection. The data acquisition 
and analysis were performed using the EZStart HPLC Software (ESA Inc.).  
FluoroJade B analysis for dying neurons 
FluoroJade B (HistoChem Inc., USA) is an anionic fluorescein derivative that stains dying 
neurons with high specificity.  The FluoroJade B working solution (0.0008% in 0.1% acetic 
acid) was prepared fresh before use. Tissue sections embedded in paraffin (Control, n = 9; 
WT MPTP, n = 19; PKC -/-, n = 7) were initially warmed for 15 min at 50°C and washed in 
xylene for 5 min. This was followed by graded ethanol series (100% - 5 min, 90% - 5 min, 
70% - 5 min) and a 5-min wash in bidistilled water. The slides were then incubated with 
shaking in a 0.06% potassium permanganate solution for 30 min.  Following a 2 min wash 
with bidistilled water, slides were incubated in .0004% FluoroJade solution for 30 min. 
Slides were washed thrice with bidistilled water for 1 minute. Excess water was removed, 
and the slides were dried at room temperature for 5 min, followed by incubation in xylene for 
1 min. The slides were then coated using DPX mounting media (Sigma-Aldrich, USA) and 
microscopy analysis was carried out after 24 h. Cell numbers in the retina were quantified by 
blinded observers. 
Rotarod analysis 
The coordinated sensorimotor function (Acute MPTP, n = 19; Sub-chronic MPTP, n = 6) was 
evaluated using the rotarod test after MPTP injection. The time spent on the rod was 
observed at two different speeds: 18 rpm - mimicking walking pace, and 26 rpm - mimicking 
jogging pace. The activity of the mice was recorded prior to and 48 h after MPTP treatment. 
If the mice remained on the rod for 20 min, the trial was terminated. The average time spent 
on the rod over 3 trials was recorded. The mice were rested for at least 5-7 minutes in 
between trials to exclude fatigue. 
Open Field test for locomotor activity 
The locomotor activity of the mice (acute MPTP, n = 18; sub-chronic MPTP, n = 6) was 
observed using the VersaMax animal activity monitors (Model RXYZCM-16; Accuscan 
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Instruments Inc., Columbus, OH). The mice were recorded prior to and following MPTP 
treatment. The open field maze consists of 4 chambers, each measuring 40 × 40 × 30.5 cm. 
Infrared monitoring sensors are evenly placed (one every 2.54 cm, to a total of 16 infrared 
beams) along the perimeter of the maze, at a height of 2.5 cm above the floor. In order to 
monitor the vertical activity, two additional sets of 16 sensors, 8.0 cm high from the floor, are 
present on opposite sides. The entire maze, including a ventilated lid, is constructed of clear 
Plexiglas. Recording was carried out over a 10-minute time interval. The data collected from 
the test was analyzed using the accompanying VersaMax analyzer (model CDA-8; Accuscan 
Instruments Inc.).  
Statistical analysis 
All statistical analyses were carried out using GraphPad Prism 5.0 (GraphPad software, San 
Diego, CA). Paired t-tests were used to compare pretreatment with post-MPTP treatment 
values. Student’s t-tests, one-way ANOVA with Bonferroni’s post-test or Dunnet’s multiple 
comparison tests were used as described in the text.  Differences between groups were 
considered statistically significant for p < 0.05. 
Results 
Characterization of the Parkinsonian phenotype in wild type MPTP treated mice 
Coordinated motor activity testing: Prior to MPTP treatment, mice (n = 19) remained on the 
rod for 889.7 ± 83.47 s (mean ± SEM) and 753.5 ± 100.9 s at 18 rpm and 26 rpm speeds, 
respectively (Fig 1A). At 48 h following acute MPTP treatment, there was a significant 
reduction in the time spent on the rotarod, both at 18 rpm (345.6 ± 73.24 s; p < 0.0001, 
Paired t-test) and 26 rpm (166.1 ± 48.77 s; p < 0.0001, Paired t-test). In addition, we tested 
unrestricted movement of the mice in an open field maze (simple motor activity) and 
recorded their horizontal and vertical activities (Fig 1B, C). Similar to the rotarod, the 
recordings on the mice were performed at least 2 days prior to MPTP injection. Prior to 
MPTP treatment, mice (n = 18) had horizontal and vertical activities of 1938 ± 60.25 and 
78.06 ± 6.531, respectively. At 48 h after acute MPTP treatment, the horizontal and vertical 
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activities were significantly reduced to 756.8 ± 129.9 (p < 0.0001, Paired t-test) and 13.06 ± 
5.237 (p = 0.0001, Paired t-test), respectively.  
Dopamine quantification: The establishment of the Parkinsonian phenotype was further 
confirmed by the quantification of striatal and ocular dopamine content using HPLC analysis 
(Fig 2A). We observed a significant reduction (p < 0.0001, Student’s t-test) in total dopamine 
content in the striatum following MPTP treatment (0.8547 ± 0.1857 ng/ml, n = 10) when 
compared to control tissue (40.63 ± 1.949 ng/ml, n = 4). HPLC analysis was also conducted 
for dopamine content in the eyes of MPTP treated animals (Fig 2B). Control eyes had 0.0729 
± 0.02449 ng/ml (n = 4) dopamine, while acute MPTP-treated wild-type mice had 0.02913 ± 
0.0026 ng/ml (n = 8) dopamine. This reduction in the dopamine content was significant (p = 
0.0048, Student’s t-test). 
Pattern ERG analysis of MPTP treated mice 
The pERG (representative pERG graph, Fig 3) from all mice (n = 22) was recorded at least 2 
days prior to MPTP treatment, and their baseline amplitudes and latencies were recorded (Fig 
4). The pretreatment (control) N35-P50 amplitude was 7.039 ± 0.56 µV (mean ± SEM) and 
the P50-N95 amplitude was 8.78 ± 0.50 µV; the N35-P50 latency was 44 ± 2.21 ms, and the 
P50-N95 latency was 78.84 ± 4.35 ms. Following acute MPTP treatment (48 h post final 
injection), pERGs were recorded and we observed significant deficits in both amplitudes and 
latencies when compared to baseline recording values (Fig 3). We observed N35-P50 
amplitude of 4.38 ± 0.43 µV (p < 0.0001, Paired t-test) and P50-N95 amplitude of 4.42 ± 
0.40 µV (p < 0.0001, Paired t-test); the N35-P50 latency was 32.47 ± 2.04 ms (p = 0.0005, 
Paired t-test) and the P50-N95 latency was 53.23 ± 3.47 ms (p < 0.0001, Paired t-test). 
Sub chronic MPTP treatment 
To study the effect of less acute toxic insult, we induced a sub chronic MPTP exposure in 
wild type mice (n = 10). After baseline values were recorded, the pERG amplitudes in these 
mice were recorded starting on day 1, 3, 4, 9 and 16 after initiation of MPTP treatment (Fig 
5). The baseline N35-P50 amplitude was 5.17 ± 0.65 µV and the P50-N95 amplitude was 
7.76 ± 0.82 µV. On day 3, the N35-P50 amplitude was 5.87 ± 0.75 µV and the P50-N95 
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amplitude was 7.03 ± 0.91 µV. On day 5, N35-P50 amplitude was 4.18 ± 0.49 µV and the 
P50-N95 amplitude was 4.07 ± 0.36 µV. On day 9, N35-P50 amplitude was 4.44 ± 0.71 µV 
and the P50-N95 amplitude was 4.68 ± 0.67 µV. On day 16, N35-P50 amplitude was 3.48 ± 
0.58 µV and P50-N95 amplitude was 4.02 ± 0.44 µV. We observed a statistically significant 
reduction in P50-N95 amplitudes at days 9 and 16 (Fig 5 B), when compared to pretreatment 
values (p = 0.001, One-way ANOVA with Dunnet’s multiple comparison test). However, 
only the P50-N95 amplitudes (on these days) were significantly smaller when compared to 
pretreatment values (p = 0.001, One-way ANOVA with Bonferroni’s post-test). No 
significant changes were observed in the rotarod and open field tests following subchronic 
MPTP treatment (data not shown). 
Full field ERG analysis of MPTP treated mice 
Analysis of the full-field ERG was carried out using the ISCEV protocol. Baseline recordings 
were obtained on all mice at least 2 days prior to acute MPTP treatment. Full field ERGs 
were then recorded again 48 h post acute MPTP treatment. We observed baseline amplitudes 
of 144 ± 21 µV (n = 4) for the scotopic combined a-wave, 903.9 ± 45.5 µV (n = 4) for the 
scotopic combined b-wave, and 693.2 ± 30.19 µV (n = 4) for oscillatory potentials (Fig 6). 
Following acute MPTP treatment, we observed a significant reduction of oscillatory 
potentials (551.8 ± 25.17 µV; p = 0.0112, Paired t-test). However, the amplitudes of the 
scotopic combined a-wave (114.6 ± 25.33 µV; p = 0.3899, Paired t-test) and b-wave (796.4 ± 
47.72 µV; p = 0.1274, Paired t-test) did not differ significantly from pretreatment values. 
Optical coherence tomography analysis of RNFL thickness in MPTP treated mice 
The structural retinal integrity following the acute MPTP treatment was evaluated using 
optical coherence tomography. The linear scans of the superior-temporal retina (area 
centralis) from the region corresponding to macula in primates were analyzed for thickness 
of the retinal nerve fiber layer (RNFL, Fig 7A). Baseline recordings were obtained at least 2 
days before initiating the acute MPTP treatment. The pretreatment RNFL thickness were 
42.05 ± 0.97 µm (n = 4). At 4 months post acute MPTP treatment, we observed a significant 
increase in the RNFL thickness (47.95 ± 1.38 µm; p = 0.0277, Paired t-test) (Fig 7B).  
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RGC function is significantly preserved in protein kinase Cδ deficient mice after MPTP 
treatment  
In order to evaluate whether PKCδ has a role in the RGC deficits induced by the MPTP 
treatment, we evaluated mice genetically deficient for PKCδ (PKCδ-/-) (n = 8). Baseline 
pERG amplitudes (before MPTP treatment) were not significantly different in PKCδ-/- mice 
when compared to wild type animals (N35-P50 = 8.48 ± 0.51 µV, p = 0.053, Student’s t-test; 
P50-N95 = 9.50 ± 0.69 µV, p = 0.3113, Student’s t-test; data not shown). Significantly better 
pERG amplitudes were observed in PKCδ-/- mice when compared to the pERG recordings 
from wild type mice after MPTP treatment. Following acute MPTP treatment, the PKCδ-/- 
mice had N35-P50 amplitude of 6.877 ± 0.722 µV, which was significantly higher compared 
to wild type mice which had N35-P50 amplitudes of 4.38 ± 0.43 µV (p = 0.002, Student’s t-
test, Fig 8A). Similar results were observed with the P50-N95 amplitude: PKCδ-/- mice had 
P50-N95 amplitude of 7.77 ± 0.599 µV, which was significantly higher compared to wild 
type mice (p = 0.0002, Student’s t-test, Fig 8B). We did not observe significant reduction in 
P50-N95 pERG amplitudes in the PKCδ-/- mice after MPTP treatment when compared to 
pretreatment values (p = 0.0585, Paired t-test; data not shown).  
Quantification of positively stained cells in the RGC layer (Fig 8C) revealed 3.4 ± 1.07 cells 
in wild-type control mice (n = 5), 4.7 ± 1.16 cells (n = 7) in wild-type mice treated with 
MPTP, and 4 ± 1.22 cells (n = 4) in PKCδ-/- mice treated with MPTP; no significant 
difference in cell numbers were observed (p = 0.4, One-way ANOVA) among the groups.   
A comparison of the coordinated motor activity (rotarod test; Fig 8D) was performed in wild-
type and PKCδ-/- mice. Prior to MPTP treatment, PKCδ-/- mice spent 680.44 ± 228.16 s (18 
rpm) and 306.33 ± 98.81 s (26 rpm) on the rotarod. The acute MPTP treatment resulted in a 
decrease of rotarod time in wild type and PKCδ-/- mice.  However,  PKCδ-/- mice spent 531.3 
± 38.23 s (18 rpm) and 194.3 ± 23.52 s (26 rpm) on the rotarod, which was significantly 
better compared to MPTP treated wild type mice: 87.6 ± 17.19 s (18 rpm, p < 0.0001, 
Student’s t-test) and 12.5 ± 3.29 s (26 rpm, p < 0.0001, Student’s t-test).  
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Discussion 
A significant body of literature has described the effects of PD on the retina and higher visual 
centers, which result in visual abnormalities such as visual hallucinations, decreased visual 
acuity, decreased color and contrast sensitivity and decreased motion perception 115,264,272-280.  
While PD diagnostic and therapeutic strategies are focused on the central nervous system, 
there is a growing need for a better understanding of PD effects on the retina and optic nerve 
in PD patients.  Data from several studies have described visual abnormalities as a cause for 
a decreased quality of life in PD patients. This necessitates the development of therapeutic 
treatments for retina and optic nerve abnormalities for this patient population264,272.    
We have used the well-accepted mouse model of MPTP exposure in order to evaluate the 
retina and optic nerve abnormalities associated with an experimentally induced PD. 
Systemically administered MPTP is converted to its toxic cation 1-methyl-4-
phenylpyridinium (MPP+) by nondopaminergic neurons and glial cells.  Following 
conversion MPP+ is exported to the extracellular space where it is actively transported in 
dopaminergic neurons by dopamine transporter system (DAT)62. After incorporation in 
dopaminergic neurons, MPP+ causes mitochondrial impairment, which results in 
degeneration and death of dopaminergic neurons, a decrease in striatal dopamine levels and a 
PD phenotype281. 
We have demonstrated that MPTP treatment in mice results in a dramatic reduction of striatal 
and ocular dopamine levels and also causes significant sensorimotor deficits. Similar results 
have been previously reported in monkeys and rabbits after acute MPTP exposure282,283. We 
have performed a detailed characterization of retinal ganglion cell function and structure 
using pERG and OCT analysis and demonstrated significant retina functional and structural 
deficits as previously reported in human PD patients and an experimentally induced PD-like 
condition in animals254,284-286. It has been previously demonstrated that PD impairs function 
of the retina dopaminergic system, which primarily results in abnormalities of amacrine cells 
and retinal ganglion cells dependent on dopamine as a neurotransmitter132,286-288. 
Electrophysiological studies from human patients and experimental PD models showed 
deficits in oscillatory potentials (generated by amacrine cells) and the P50-N95 component of 
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the pERG amplitude (generated by retinal ganglion cells)259,262,287-289. Histological analysis of 
human and experimental animal retinal tissue showed degenerative changes and intracellular 
inclusion accumulation associated with cells in the GCL and INL 283,290,291.  Our functional 
and structural studies confirmed that a similar type of change exists in a mouse model of 
MPTP exposure. Furthermore, we have also demonstrated that sub chronic MPTP treatment 
results in much milder damage. Similar patterns of retinal damage have been described in a 
primate model of MPTP induced PD292. 
Several studies using OCT analysis of the RNFL in PD patients have shown significant 
thinning of the inferior peripapillary RNFL285 254. Furthermore, an early decrease in RNFL 
thickness has been reported in PD patients with early clinical signs of the disease, even 
before the onset of any visual deficits 265. However, a recent study on 32 patients with PD did 
not find significant difference in RNFL or macular thickness when compared to healthy 
control293. In our experimental study, we have observed a significant increase in the RNFL 
thickness at 4 months after acute MPTP treatment. Further, Fluoro-Jade analysis for dying 
neurons at acute time-points did not reveal significant cell death in the retina. We 
hypothesize that such an increase in RNFL thickness could be a result of early gliosis at the 
optic nerve, which could eventually lead to RNFL thinning. Since evaluation of the retina 
and optic nerve function and structure can be objectively achieved using OCT and ERG, this 
methodology could also provide a sensitive and objective assessment of therapeutic value of 
novel PD drugs administered systemically294,295, especially in the light of recent data which 
has shown a good correlation between retinal morphological and functional findings and 
clinical severity scores in Parkinson's disease284. These techniques coupled with the power of 
transgenic mouse models could dramatically accelerate the discovery and objective 
evaluation of novel drug candidate compounds for treatment of PD. 
An important finding of this study is the lack of retinal deficits in PKCδ-/- mice exposed to 
acute MPTP administration. Previous studies have demonstrated a strong role of PKCδ in 
dopaminergic neuronal death266,296,297. PKCδ is a member of a family of serine- and 
threonine-specific protein kinases, and may have pro-apoptotic or pro-survival properties298. 
Proteolytic cleavage of PKCδ due to increased activation of caspase-3 (most frequently as a 
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result of increased oxidative stress) results in the auto-regulatory enhancement of caspase-3 
activity and strong pro-apoptotic activity that has been implicated in the degeneration of 
dopaminergic neurons 266,298. Furthermore, cleaved PKCδ can phosphorylate phosphatase 2A 
(PP2A), which results in a dephosphorylation and inhibition of tyrosine hydroxylase and an 
ultimate decrease in dopamine production. 
Our experimental results are strongly suggestive of the important role of PKCδ in retinal 
deficits, since PKCδ-/- mice had significantly better RGC function observed by pERG 
analysis when compared to wild-type after MPTP exposure. Considering increased PKCδ 
expression in brain tissue of human PD patients (A. Kanthasamy, unpublished observation), 
it is likely that pharmacological targeting of this particular kinase may be a therapeutic 
strategy for treatment of PD patients296. While the goal of any PD treatment remains systemic 
treatment, which should result in adequate drug levels in the brain, targeting of PKCδ by 
using topical (eye drop) administration or intravitreal drug delivery may become an 
important additional therapeutic approach for treatment of PD associated retina and optic 
nerve abnormalities. Considering that targeted ocular drug delivery could be safely utilized 
for different pharmacological agents, which may not have adequate systemic therapeutic 
effects, or have unacceptable side effects after systemic administration, ocular therapeutics 
may be a relatively safe approach for treatment of PD patients suffering from visual 
abnormalities.  
In conclusion, we have demonstrated that the MPTP inducible model of PD in mice is 
characterized by significant functional and structural retinal deficits, which correspond well 
to changes seen in human PD population. Furthermore, we have demonstrated that PKCδ 
may have an important role in retinal neuronal dysfunction and death in a Parkinson’s-like 
pathology. Considering the availability of different transgenic animals and the extensive 
molecular tools for mouse studies, it is likely that mouse based studies may provide an 
opportunity for better understanding of visual system abnormalities associated with PD and 
the development of novel therapeutic strategies in the future.  
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Figure Legends 
Figure 1: The establishment of a Parkinsonian phenotype was determined by behavioral tests 
for the coordinated (A) and simple motor activity (B, C). MPTP treatment caused significant 
deficits in both tested parameters .Bars represent mean ± SEM.  
Figure 2: A reduction in dopamine content is a well-recognized feature of PD. The dopamine 
content in the striatal region of the brain (A) and in the eye (B) of control and MPTP-treated 
mice was evaluated. When compared to control tissue, a significant reduction in total 
dopamine content in the striatum and in the eyes following MPTP treatment was observed.  
Figure 3: Representative pattern-evoked electroretinography (pERG) results from control (A) 
and MPTP treated (B) C57Bl/6 mice.  
Figure 4: At 48 h post acute MPTP treatment, we observed significant deficits in both N35-
P50 and P50-N95 amplitudes; however, no significant differences were observed in the 
latencies when compared to baseline recordings. 
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Figure 5: The sub-chronic MPTP treatment is a less acute insult that helps better mimic 
actual degeneration that occurs in PD. Recordings were performed out on days 3, 5, 9, and 16 
post injection. A reduction in the P50-N95 amplitude was observed  on days 9 and 16, and 
the N35-P50 latency was significantly reduced on day 16 (B, C). No significant differences 
were observed in the other parameters on the measured days.  
Figure 6: Representative full-field ERG results from control and MPTP treated C57Bl/6 mice 
(A). Following MPTP treatment, a significant deficit in the amplitude of the oscillatory 
potentials was observed (B). The amplitudes of the scotopic combined response a-wave and 
b-wave (C, D) did not differ significantly from pretreatment values. 
Figure 7: OCT scan analysis of the RNFL revealed a significant thickening in MPTP-treated 
mice. The OCT scan was recorded from the superior-temporal region, the region of the retina 
corresponding to the area centralis in higher mammals (A). Demarcation of the layers of the 
retina with a RNFL being delineated with red lines (B).  At 4 months post acute MPTP 
treatment, we observed a significant increase in the RNFL thickness (C).  
Figure 8: PKCδ knockout mice exposed to acute MPTP treatment had significantly better 
N35-P50 (A) and P50-95 amplitudes (B) compared to wild type mice. Quantification of cell 
death in the RGC layer (C) revealed no significant difference in the number of dying neurons 
in MPTP-treated wild type mice retina when compared to control and PKCδ-/- retina. 
Significant preservation of motor activity, evidenced by performance on the rotarod, was 
observed. 
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CHAPTER IV.  FUNCTIONAL AND STRUCTURAL EVALUATION OF 
RETINA AND OPTIC NERVE IN AN EXPERIMENTAL RODENT 
MODEL OF BLAST EXPOSURE 
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Abstract 
Purpose: To evaluate retina and optic nerve function and structure after blast exposure. 
Methods: Healthy adult male C57/Bl6 mice were exposed to a blast wave (137 kPa) within a 
blast chamber.  Retina and optic nerve function and structure were evaluated using the 
chromatic pupil light reflex (cPLR), full-field and pattern electroretinography (ERG) and 
spectral-domain optical coherence tomography (SD-OCT).  Histological analysis of the 
retina and optic nerve was performed at the termination of the study.  
Results: A significant decrease in pattern ERG (P50-N95) amplitudes was observed in 1-
year-old mice exposed to blast at 2 months (n=9, 6.2±0.6 µV,mean±SEM), 4 months (n=9, 
5.5±0.6 µV) and 8 months (n=11, 6.2±0.6 µV) of age when compared to healthy 1-year-old 
control animals (n=20, 8.5±0.5 µV; p=0.003, one-way ANOVA with Dunnet’s multiple 
comparison test). Assessment of the cPLR demonstrated decreased maximum pupil 
constriction diameter in blast-injured mice (n=12) using red light (ctrl=1.12±0.05 mm; 
blast=1.38±0.07 mm; p=0.0063, Student’s t-test) or blue light stimuli (ctrl=0.57±0.03 mm; 
blast=0.71±0.03 mm; p=0.0008, Student’s t-test) 24h after blast exposure compared to 
control mice (n=9). Three months following blast exposure a significant thinning of the 
superior-temporal peripapillary retinal nerve fiber layer was observed (n=5) compared to 
control animals (n=11) using SD-OCT (ctrl=61.1±0.9 µm, blast=56.4±1.7 µm; p=0.0217, 
Student’s t-test).  
Conclusions: Blast exposure in mice is associated with a mild, but persistent functional and 
structural optic nerve deficits.  Utilization of non-invasive functional and structural 
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examination techniques may be a useful approach for early detection of visual system 
abnormalities in blast-exposed subjects. 
Introduction 
The widespread use of improvised explosive devices (IEDs) in recent military conflicts has 
increased the prevalence of blast-mediated injuries in soldiers.  Blast-mediated injuries are 
the leading cause of combat-related injuries in Operations Enduring and Iraqi Freedom 
(OEF/OIF), leading them to be designated as the signature injury of these conflicts141. 
Residual physical symptoms reported after blast exposure include headache, nausea, light 
and noise sensitivity, and visual disturbances, among others175.  In addition to the cognitive 
and neurobehavioral symptoms experienced by soldiers following TBI, a number of 
somatosensory abnormalities have been documented, with visual and auditory disturbances 
being predominantly observed142-145. 
Many blast exposed subjects suffer from damage to the visual system150  and similar visual 
disturbances have been described also in civilian population after mild, moderate or severe 
TBI episodes. Lachapelle et al190 carried out a long-term analysis of visual event-related 
potentials (VERPs) in 17 patients with mild TBI, who presented deficits in complex visual 
integrative tests.  A significantly delayed latency was observed in texture segregation 
paradigms by TBI patients. Furthermore, reduced amplitude and delayed latency of the 
VERP P300 component has been observed in patients with moderate TBI191. Recently, 
chronic visual dysfunction has been documented in subjects with TBI caused by exposure to 
blast waves147,299-301. Cockerham et al302 reported that 20 of 46 patients with blast-mediated 
injuries had evidence of closed-globe eye injuries, although the visual acuity of most eyes 
remained normal.  Other visual system disorders in these patients include photosensitivity, 
oculomotor difficulties, and binocular vision deficits147-149, which have been found to persist 
up to one year post-injury303.   
The primary purpose of this study was to characterize retina and optic nerve deficits in a 
rodent model of blast injury. To achieve this, we have utilized a battery of tools to analyze 
structure and function of the retina and optic nerve. We have also characterized the 
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expression of oxidative stress markers in the retina to better understand the molecular 
consequences of blast exposure.  
Methods 
Animals 
All animal studies were conducted in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and were approved by the Iowa City Veterans 
Affairs Institutional Animal Care and Use Committee.  Adult healthy male C57BL/6 mice (8 
weeks old) were used for the purpose of this study. 
Blast injury 
Mice were anesthetized using the 4% halothane with 0.8 L/min oxygen flow using the 
custom made blast chamber (BioMed Vision Technologies, Ames, IA). The blast chamber 
had two parts divided by opening which was fitted with a plastic mylar membrane that 
ruptures at 20 ± 0.2 psi (mean ± SEM) pressure. Once when one part of the chamber is 
pressurized and reaches the pressure of 20 psi, the mylar membrane ruptures, resulting in the 
blast wave propagation in the chamber.   Mice were subsequently positioned in the animal 
holder, which was padded to prevent blunt head injury against the rigid walls of the animal 
holder. The animal holder is fixed within the blast chamber with the left side of the head 
oriented toward the blast opening at a distance of 30 cm (Fig. 1).  A continuous flow of 4% 
halothane anesthesia was maintained while the mouse was in the chamber using a soft 
flexible nose cone connected through a one-way port in the side of the blast chamber.  Only 
the head of the mouse was exposed, with the rest of body was shielded from the blast wave, 
with a goal of preventing interaction of blast wave with any body structures beside the head 
region.   Immediately following exposure to the blast wave animals were placed on a heating 
pad and provided with 100% oxygen to facilitate recovery from general anesthesia and to 
prevent hypothermia. Analgesic agent (buprenorphine – 0.01 mg/ml) was provided in 
drinking water for 5 days after blast exposure. 
Pattern electroretinography 
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Pattern evoked electroretinography (pERG) was used to objectively measure the function of 
the retinal ganglion cells by recording the amplitude and latency of the pERG waveform.  
Mice (n=79) were initially anesthetized with 3.5% halothane and 0.8 L/min oxygen until 
unresponsive to the righting reflex. They were subsequently maintained using 1.75% 
halothane, 0.8 L/min oxygen, and 0.4 L/min nitrous oxide for the duration of recording. The 
mice were placed on a stainless steel recording table equipped with a hot-water based 
warming platform to maintain body temperature. Pupils were dilated using a 1% tropicamide 
solution. The mice were positioned 20 cm from the stimulus monitor with the head angle 
tilted at 45 degrees to provide direct exposure of the stimulus to the visual axis of the 
recorded eye.  Pattern ERG responses were evoked using alternating, reversing, black and 
white vertical stimuli delivered on a monitor with a Roland Consult ERG system (Roland 
Consult, Brandenburg, Germany).  Each animal was placed at the same fixed position in 
front of the monitor to prevent recording variability due to animal placement.  Stimuli (9° 
full field pattern, 1 Hz frequency, 200 averaged signals with cut off filter frequencies of 1-30 
Hz, 98% contrast, 80 cd/m2 monitor illumination intensity) were delivered under photopic 
conditions, since slower stimulation rates in mesopic and scotopic conditions can elicit rod-
mediated full field ERG responses, which can completely conceal the pERG response. The 
pERG response was evaluated by measuring the amplitude (N35-P50 and P50-N95) and 
implicit time of the waveform.  Implicit times were calculated for the N35-P50 and P50-N95 
components.  
Full-Field Electroretinography 
Mice (n=17) were dark adapted for 12 hours prior to recording the full-field ERG.  Animals 
were initially anesthetized with 3.5% halothane and 0.8 L/min oxygen until unresponsive to 
the righting reflex.  Animals were subsequently maintained using 1.75% halothane, 0.8 
L/min oxygen, and 0.4 L/min nitrous oxide for the duration of recording.  Pupils were dilated 
using 2.5% phenylephrine and 1% tropicamide applied to the cornea. Animals were 
positioned on a heated stage to maintain body temperature during anesthesia and recording 
sessions.  Ground and reference electrodes were placed subcutaneously in the tail and 
forehead of the animal, respectively. A solid recording electrode (Roland Consult) was 
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placed on each eye in contact with the cornea, and a thin layer of methylcellulose was used to 
maintain contact between the cornea and electrode and to decrease the recording noise.  
Following placement of the electrodes, animals were dark adapted for an additional 30 
minutes prior to recording.  An automated ERG protocol was used to evaluate the 
electroretinographic parameters.  The ERG recordings were performed using the Reti-Port 
system (Roland Consult).  Scotopic rod responses (illumination 0.22 cd/m2, cut off frequency 
1-300Hz, n = 8 responses were averaged) were collected first, followed by the scotopic 
maximum combined response (78 cd/m2, 1-300 Hz, n = 8 responses were averaged), 
oscillatory potentials (78 cd/m2, 200-500 Hz, n=8 responses were averaged), photopic cone 
response (21 cd/m2 rod bleaching background light in combination with 78 cd/m2 stimulation, 
1-300 Hz, n = 8 responses were averaged), and the flicker ERG response (78 cd/m2, 1-300 
Hz, n = 50 responses were averaged).  The ERG responses were subsequently analyzed using 
the RETIport32 software (Roland Consult). 
Phenol red thread tear test 
Zone-Quick (Showa Yakuhin Kako Co. Ltd., Japan) phenol red thread (PRT) test (n=9) was 
used to analyze tear production. The test uses a sterilized PRT that changes color from 
yellow to red when in contact with tears. With one end bent, the thread can be placed onto 
the palpebral conjunctiva. Once the thread was placed on the lower eyelid, 30 seconds were 
counted, following which, the thread was removed. The length of color change from yellow 
to red was recorded.  
Chromatic Pupil Light Reflex 
The chromatic pupil light reflex (cPLR) evaluation was performed using a Melan-100 
instrument (BioMed Vision Technologies, Ames, IA,).  Mice (n=35) were awake during the 
recording session and were held still using minimal manual restraint. Recording sessions in 
most animals lasted less than one minute.  The intensity of the diode based light sources 
were: 630 ± 3 nm for red light, luminance 200 kcd/m2, and 480 ± 3 nm for blue light, 
luminance 200 kcd/m2.  Baseline pupil diameter measurements in mice were taken in 
darkness prior to illumination using an infrared video camera (Sony Handycam, Sony 
Corporation).  A red light stimulus with a two second duration was used to illuminate one 
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eye of the mouse at a distance of 4 cm from the ocular surface.  The direct pupil constriction 
responses were recorded from the illuminated eye with a digital infrared camera.  Prior to 
performing illumination with the blue light, pupils were allowed to completely dilate to 
baseline diameter.  Captured digital movies of pupil responses were analyzed using Adobe 
Photoshop (v. 10.0.1, Adobe Systems, Inc.). A calibrated dot grid with dot sizes of 0.5, 1, 
1.5, 2 and 3 mm in diameter was recorded from a distance of 4cm to calculate a regression 
equation so calculation of the absolute pupil diameter from the recorded image could be 
performed. 
Spectral domain optical coherence tomography  
Spectral domain optical coherence tomography (SD-OCT) analysis was performed on 
anesthetized mice (n=16) using a Spectralis SD-OCT (Heidelberg Engineering, Vista, CA) 
imaging system, coupled with a 25D lens for mouse ocular imaging (Heidelberg Engineering, 
Vista, CA) 3 months following blast injury.  Mice were anesthetized using a 3% halothane 
and 0.8 L/min oxygen mixture on a heating pad to maintain body temperature.  Pupils were 
dilated using a 1% tropicamide solution. The cornea was moisturized with a saline solution, 
which was applied every 20-30 seconds.  Circular scans around the optic nerve region were 
performed to quantify the retinal nerve fiber layer (RNFL) thickness.  Circular scans were 
subsequently analyzed by including or excluding blood vessels from the RNFL thickness 
calculation, since blood vessels in rodents are almost completely embedded in the RNFL235 
and are included in automated RNFL measurement routines. 
Histopathology and morphology analysis of the retina and optic nerve 
Immunohistochemical procedures were used to examine the expression profile of proteins 
associated with oxidative and endoplasmic reticulum stress in the retina after blast-mediated 
injury.  Briefly, paraffin embedded sections of the retina were re-hydrated using xylene and 
decreasing concentrations of ethanol followed by a final rinse with potassium phosphate 
buffered solution (KPBS).  Heat-mediated antigen retrieval was performed using citrate 
buffer. Tissue was incubated in a blocking solution containing 0.1% bovine serum albumin 
(BSA, A9647, Sigma), 0.04% Triton X-100 (Fisher), and 5% normal donkey serum (NDS, 
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017-000-121, Jackson ImmunoResearch, West Grove, PA) in KPBS.  Primary antibodies 
(Table 1) were diluted in blocking solution and incubated overnight at room temperature.  
Tissue was rinsed with KPBS containing Triton X-100, and incubated with Cy-3 conjugated 
secondary antibodies for 2 hours.  Following rinses, 4’, 6’-diamidino-2-phenylindole, 
dilactate (DAPI, 1 µg/ mL, D3571, Sigma) was applied for 30 min at room temperature in 
order to visualize nuclei.  Slides were mounted with an anti-fade mounting media and sealed.  
Negative controls were processed in parallel by omission of the primary or secondary 
antibody.  Tissue was examined using a Leica DM5000B microscope.  Micrographs were 
prepared using Adobe Photoshop (CS3, Adobe, San Jose, CA) and Adobe Illustrator (CS3).  
Ultrathin sections of optic nerves were examined by electron microscopy.  Briefly, optic 
nerves (dissected 1 mm posterior to the sclera) were postfixed in a solution containing 2% 
paraformaldehyde-2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and then rinsed in 
cacodylate buffer, postfixed in 2% osmium tetroxide in cacodylate buffer, dehydrated in 
alcohol, and embedded in epoxy resin.  Cross sections (1 µm thick) were cut with an 
ultramicrotome, mounted on glass slides and stained with 1% toluidine blue.   
Results 
Blast exposure 
The method of blast injury described here (Fig. 1) resulted in 3% mortality of mice exposed 
to the blast wave within the first two minutes after injury.  All surviving animals had 
physiologically normal appearance 60 minutes after blast exposure, including normal 
motility, grooming and behavior. We did not observe delayed mortality at later times due to 
blast exposure.  
Pattern Electroretinography 
For analysis of the pERG parameters acutely following blast exposure, the baseline pERG 
response amplitudes and latencies from all mice (n =30) were recorded at least 2 days prior to 
blast exposure (Fig 2).  Animals were euthanized at each time point after pERG recording 
and tissue collected for histological analysis.  The pre-recorded baseline N35-P50 amplitude 
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was 5.6 ± 0.44 µV (Fig 2A; mean ± SEM). Following blast exposure, pERGs were recorded 
at 1 hour (n=11), 12 hours (n=9), and 24 hours (n=10) post injury.  A statistically significant 
reduction was observed in the N35-P50 amplitude at 1 hour (3.5 ± 0.4 µV; p=0.01, Student’s 
t-test) and 12 hours (3.1 ± 0.5 µV; p=0.002, Student’s t-test) post injury, when compared to 
baseline values. However, this N35-P50 amplitude recovered to the baseline amplitude 
values at 24 hours (6.8 ± 1.2 µV; p = 0.5022, Student’s t-test) after injury (Fig. 2 A). The 
baseline P50-N95 amplitude was 9.3 ± 0.5 µV (Fig. 2 B). Following blast exposure, 
significantly reduced P50-N95 amplitudes of 6 ± 0.7 µV (p = 0.0012, Student’s t-test) and 
5.7 ± 0.9 µV (p = 0.0007, Student’s t-test) were observed at 1 hour and 12 hours post blast, 
respectively, when compared to the pre-recorded baseline amplitude.  No significant 
difference in the P50-N95 amplitude was observed at 24 hours (9.4 ± 0.9 µV; p = 0.9, 
Student’s t-test) post injury.   
The baseline N35-P50 latency was 52.3 ± 3.4 ms (Fig. 2 C, mean ± SEM).  The N35-P50 
latency was significantly decreased at 1 hour (39.8 ± 6.9 ms; p = 0.02, Student’s t-test) and 
12 hours (33.8 ± 3.9 ms; p = 0.005, Student’s t-test) following blast exposure, when 
compared to baseline latency. However, no statistically significant reduction was observed at 
24 hours post injury (46.7 ± 4 ms; p = 0.51, Student’s t-test). The baseline P50-N95 latency 
was 123.8 ± 6.8 ms (Fig. 2 D).  There was not a significant difference in the P50-N95 latency 
at 1 hour (130.8 ± 15 ms; p = 0.86, Student’s t-test), 12 hours (116.8 ± 16.1 ms; p = 0.5, 
Student’s t-test) or 24 hours (124.2 ± 14.2 ms; p = 0.98, Student’s t-test) post injury, when 
compared to the baseline value.  
In order to observe the effect of aging on chronic pERG parameters, mice were exposed to 
blast at different ages and their pERG was recorded at 1 year of age (Fig 3). Mice were 
randomly selected to be exposed to blast at either 2 months (n = 9), 4 months (n = 9), or 8 
months (n = 11) of age; pERG recordings were then carried out at 10 months, 8 months, or 4 
months post blast exposure, respectively. At 1 year of age, the N35-P50 amplitude was 6.2 ± 
0.7 µV in healthy control mice (n = 20; mean ± SEM). The N35-P50 amplitudes of the 1-
year-old blast-exposed mice (4 months post blast, 4.6 ± 0.7 µV; 8 months post blast, 5.6 ± 
0.7 µV; 10 months post blast, 5.4 ± 0.8 µV) were not significantly reduced when compared 
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to age-matched controls (Fig 3A; p = 0.47, ANOVA with Dunnet’s multiple comparison 
test). Healthy 1-year-old control mice had P50-N95 amplitude of 8.5 ± 0.5 µV. However, the 
P50-N95 amplitudes of the 1-year-old blast-exposed mice (4 months post blast, 6.2 ± 0.6 µV; 
8 months post blast, 5.5 ± 0.6 µV; 10 months post blast, 6.2 ± 0.6 µV) were significantly 
reduced when compared to age-matched controls (Fig 3B; p = 0.003, ANOVA with Dunnet’s 
multiple comparison test).    
The N35-P50 latency in healthy 1-year-old control mice was 52.7 ± 5.7 ms (mean ± SEM). 
The N35-P50 latency of 1-year-old blast-exposed mice (4 months post blast, 43.1 ± 5.8 ms; 8 
months post blast, 49.8 ± 5.3 ms; 10 months post blast, 44.1 ± 9 ms) were not significantly 
different from age-matched controls (Fig 3C; p = 0.61, ANOVA with Dunnet’s multiple 
comparison test). The P50-N95 latency in healthy 1-year-old control mice was 122.9 ± 10.3 
ms. The P50-N95 latency of 1-year-old blast-exposed mice (4 months post blast, 123.1 ± 
13.2 ms; 8 months post blast, 88.6 ± 8.8 ms; 10 months post blast, 116.7 ± 19.1 ms) were not 
significantly different from age-matched controls (Fig 3D; p = 0.35, ANOVA with Dunnet’s 
multiple comparison test).    
Full field ERG  
The baseline amplitudes of healthy control mice (n=7) were 146.0 ± 35.95 µV for the 
scotopic maximum combined a-wave, 274.5 ± 67.31 µV for the scotopic maximum 
combined b-wave, 253.2 ± 54.42 µV oscillatory potential summation, and 20.57 ± 4.69 µV 
for the flicker response (P1-N3 amplitude) (Fig 4).  There was not a significant difference in 
the full-field ERG response 7 days after blast exposure (n=10) for the scotopic maximum 
combined a-wave (Fig. 4 A; 214.9 ± 22.68 µV, p = 0.1088, Student’s t-test) or b-wave (Fig 4 
B; 427.4 ± 45.60 µV, p = 0.0694, Student’s t-test). Additionally, we did not detect significant 
differences in the oscillatory potentials (Fig 4 C; 332.7 ± 49.83 µV, p = 0.3060, Student’s t-
test) or P1-N3 flicker response amplitude (Fig 4 D; 24.62 ± 3.64 µV, p=0.5000, Student’s t-
test) seven days after injury.  
Tear production 
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Tear production was tested using the phenol red thread (PRT) test in blast-exposed mice (9 
months post blast, n = 4) and age-matched healthy control mice (n = 5). The length of color 
change on the PRT was 10.3 ± 1.1 mm (Fig. 5, mean ± SEM) and 10.5 ± 1.3 mm in healthy 
controls and blast-exposed mice, respectively. No significant difference was observed 
between both groups (p = 0.99, Student’s t-test). 
Chromatic Pupil Light Reflex 
The cPLR was used to determine the effects of blast exposure on the retina and optic nerve 
using red (630 nm) or blue (480 nm) light one day post-injury.  The resting baseline pupil 
diameter in scotopic conditions was not significantly different between control (n=9) and 
blast injured (n=12) animals (Fig. 6 A, ctrl = 2.11 ± 0.05 mm; blast = 2.11 ± 0.04 mm; p = 
0.9914).  The pupil diameter in healthy control mice decreased to 1.12 ± 0.05 mm and 0.57 ± 
0.03 mm after stimulation with red (630 nm) or blue (480 nm) light, respectively (mean ± 
SEM).  Blast exposure caused a significantly weaker pupillary constriction after stimulation 
with red (Fig 6 B, 1.38 ± 0.07mm, p = 0.0063, Student’s t-test) and blue (Fig. 6 C, 0.71 ± 
0.03, p = 0.0008, Student’s t-test) light compared to healthy control mice.  
To observe whether cPLR deficits persisted chronically following blast exposure, a similar 
analysis was carried out at 10 months post blast injury. The resting baseline pupil diameter in 
scotopic conditions was not significantly different between age-matched control (n=5) and 
blast injured (n=9) mice (Fig. 6 D, control = 2.5 ± 0.06 mm; 10 months post blast = 2.6 ± 
0.04 mm; p = 0.74, Student’s t-test).  Following stimulation with red (630 nm) or blue (480 
nm) light, the pupil diameter in healthy control mice decreased to 1.2 ± 0.07 mm and 0.7 ± 
0.08 mm, respectively (mean ± SEM).  No statistically significant difference was observed in 
the pupillary constriction of blast-exposed mice after stimulation with red (Fig 6 E, 1.3 ± 
0.06 mm, p = 0.36, Student’s t-test) and blue (Fig. 6 F, 0.68 ± 0.04, p = 0.41, Student’s t-test) 
light compared to age-matched healthy control mice.  
Optical Coherence Tomography 
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Optical coherence tomography (OCT) was used to analyze the thickness of the retinal nerve 
fiber layer (RNFL) from the superior-temporal region of the retina (Fig. 7). Age-matched 
healthy control mice (n = 11) were compared to mice that were 3 months post blast exposure 
(n = 5). The RNFL thickness in control mice was 61.1 ± 0.9 µm (mean ± SEM). Three 
months after blast exposure, there was a significant decrease in the RNFL thickness (56.4 ± 
1.7 µm, p = 0.0217, Student’s t-test) when compared to control.   
Histological analysis of the retina and optic nerve 
Pathologic analysis of the retina demonstrated a reduction in cellularity in the GCL following 
blast injury when compared to healthy control mice (Fig. 8).  Analysis of ultrastructural optic 
nerve integrity using electron microscopy revealed decreased axon density and glial scarring 
10 months after blast injury in mice (Fig. 9).  
Immunohistochemistry 
Blast injury resulted in an acute upregulation of proteins associated with oxidative stress.  
Analysis of 4-HNE (a marker for oxidative stress and lipid peroxidation) showed 
significantly increased immunoreactivity in the retina of animals exposed to blast (n=12) as 
compared to healthy controls (n=4) (Fig. 10 A; Control - 1.2 x 10-6 ± 2.5 x 10-7  (mean ± 
SEM); 1 hour post blast - 0.6 ± 0.1; p = 0.04, Student’s t-test).  Evaluation of iNOS 
expression showed a trend toward increased immunoreactivity in blast-injured mice (n=12) 
when compared to controls (n=21) (Fig. 10 B; control - 0.57 ± 0.16, 1 hour post blast - 0.91 ± 
0.19), however the difference was not statistically significant (p = 0.08, Student’s t-test).  
One hour post blast injury, beta amyloid immunoreactivity was significantly increased in the 
retina of animals exposed to blast injury (n=10) when compared to healthy control eyes 
(n=20) (Fig. 10 C, control - 0.4 ± 0.11, 1 hour post blast - 1.0 ± 0.2, p=0.03, Student’s t-test).  
However, no statistically significant difference was observed when 12 hours (n=6) and 24 
hours (n=10) post blast exposure were included in the analysis (12 hours post blast - 0.6 ± 
0.2; 24 hours post blast – 0.8 ± 0.2; p = 0.18, One-way ANOVA with Dunnet’s multiple 
comparison test). 
Discussion 
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Many retrospective studies conducted on soldiers returning from the recent wars have found 
increased incidence of visual disturbances following exposure to blast wave150,151,155,178,303. A 
recent study by Brahm et al 150 found 33% of all returning veterans to have some form of 
visual dysfunction primarily due to blast exposure. Commonly reported visual symptoms 
include diplopia, fixation instability, nystagmus, and blurred vision; in addition, abnormal 
vestibular ocular reflex, convergence insufficiencies, corneal injury, and oculomotor palsies 
have been observed clinically149.  
In our study we have demonstrated that a single blast exposure episode results in the mild 
functional and structural damage to the optic nerve.  Subsequent histological analysis 
demonstrated very minimal and focal axonal damage in optic nerves of mice exposed to the 
blast. We have demonstrated that functional recording (pERG) of optic nerve function seems 
to be the most sensitive test for detection of blast-induced optic nerve abnormalities. 
Previous studies showed that functional evaluation of evoked potentials (EP) and event-
related potentials (ERP) can be potentially utilized in the assessment of the CNS functional 
status and prediction of ultimate clinical outcome after TBI181. Of these, visual ERP (VERP) 
are valuable indicators of visual pathway integrity and cognitive function. In a VERP study 
on 17 patients with mild TBI 190, TBI patients presented with deficits in complex visual 
integrative tests and significantly delayed latencies in texture segregation paradigms 
compared to control subjects. Several studies have also documented abnormalities in the 
visual P300 component in patients with mild and moderate TBI189,191,192.  
While the vast majority of studies in human patient population described visual disturbances 
in blast patients, which could be predominantly attributed to the damage in the brain centers 
or efferent pathways controlling the oculo-motor control, there are relatively sparse data 
about the effect of blast exposure on the retina and optic nerve function. In this study we 
have demonstrated that even single episode of relatively mild blast exposure may result in 
detectable damage to the optic nerve. Our experimental design could not effectively address 
the possible mechanism of the optic nerve injury after blast exposure, however previous 
studies suggested that rapid propagation of the blast wave results in shearing forces, which 
can particularly damage long axonal tracts. This notion is potentially supported by previous 
studies which demonstrated diffuse axonal injury (particularly in long axonal tracts) in 
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experimental animal models of blast exposure by using the shock tube 161-165.   Two 
experimental studies looks specifically in the morphological properties of the optic nerve 
after TBI. In one study, rats exposed to blast overpressure of 129-173 kPa had extensive 
axonal degeneration of the optic nerve, optic tracts, lateral geniculate body, and superior 
colliculus170. A recent study using the fluid percussion model of TBI has demonstrated 
possible damage to the optic nerve vasculature at the level of bony canal resulting in 
Wallerian degeneration within 48 hours of injury171.  
Our study has several important findings related to the mechanism of blast-induced optic 
nerve injury. It seems that even relatively mild blast exposure can result in the minimal, but 
detectable optic nerve damage, which creates the concern about the optic nerve status in 
individuals exposed to the multiple blasts over the course of active duty. Our study is also 
suggestive of the possible immediate nature of the optic nerve injury, which does not seem to 
have a progressive nature. Our molecular data support this notion, since it seems that the 
most prominent change occurs in the early period post blast exposure (1 h post blast) with 
gradual normalization of changes over the course of 12-24h post exposure. Most importantly, 
our study demonstrated that age of the subject does not change the predisposition to the optic 
nerve injury after blast exposure (young and old mice had almost identical level of functional 
optic nerve deficits). Results of this study further support the critical need for the careful and 
thorough evaluation of the optic nerve function and structure in individuals exposed to the 
blast effects.  
Considering that the last decade resulted in significantly increased activities resulting in the 
massive civilian and military exposure to the action of explosive devices, there is a 
significant concern that blast-induced CNS and visual system pathology may become more 
frequently encountered entity by ophthalmologists. Probably the most critical care has to be 
dedicated to the visual examination and rehabilitation of returning veterans, which were 
exposed to the multiple blast episodes, and may be at risk of having the significant long term 
consequences for their visual system function.   
Conclusion 
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It has been demonstrated in previous studies that the acute symptoms of blast injury typically 
resolve rapidly, although chronic, progressive cognitive, somatic and affective disorders may 
manifest months to years after the initial injury. Our results are supportive of these previous 
findings. We observed chronic optic nerve dysfunction following exposure to a single blast 
wave. This is also accompanied by mild structural abnormalities, predominantly at the level 
of the ganglion cell layer, retinal nerve fiber layer, and the optic nerve. These results argue 
for diffuse axonal injury as the primary pathology of the optic nerve following blast 
exposure. Utilization of non-invasive analyses of visual function may allow for better 
identification of individuals with TBIs.  
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Tables 
Table 1: Antibodies used in this study 
Primary Antibody Source Dilution 
anti-4HNE Abcam (ab48506) 1:150 
anti-Beta Amyloid Abcam (ab2539) 1:100 
anti-iNOS Abcam (ab15323) 1:200 
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Figure 10 
 
Figure Legends 
Figure 1: A schematic of the blast chamber showing (A) the two halves of the tank closed 
together.  A small port in one half of the tank is covered with a mylar membrane to generate 
the blast wave, which is sealed in place using a locking metal ring (B). The anesthetized 
mouse is held securely in a padded animal holder, with the left side of the head facing the 
blast wave at a distance of 30 cm from the mylar membrane and the rest of the body shielded 
from the blast wave.  
Figure 2: Acute pERG deficits following blast injury. pERG was recorded at 1 h (n=11), 12 h 
(n=9), and 24 h (n=10) post blast. Significant deficits were observed in the N35-P50 
amplitude at 1 h and 12 h compared to baseline parameters that recovered by 24 hours post 
injury (A). Similarly, a significant reduction was observed in the P50-N95 amplitude at 1 h 
and 12 h following blast injury; by 24 h, the P50-N95 amplitude was not significantly 
different from baseline parameters (2B). In the N35-P50 latency parameter, there was a 
significant deficit at 1 h and12 h, which recovered by 24 h (2C). No significant changes were 
observed in the P50-N95 latency values before and after blast injury (2D). 
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Figure 3: Chronic pERG deficits occur following blast injury, regardless of the age of the 
animal when injury was induced. Two month old mice (n=9), 4 month old mice (n=9) and 8 
month (n=11) old mice were exposed to the identical blast injury and their pERG function 
was evaluated at 1 year of age, with a goal of evaluating possible age related susceptibility to 
the optic nerve damage. A significant reduction of the P50-N95 amplitude was observed in 
all groups of blast exposed mice at 1 year of age when compared to age-matched controls 
(n=20) (3B). The deficit at this time point occurred regardless of the age at which they were 
subjected to the blast injury. No significant deficits were observed in the other pERG 
parameters. 
Figure 4:  Full-field ERG responses are not affected by blast exposure. At 7 days post blast 
(n=10), no significant difference was observed in the maximum combined scotopic ERG a-
wave (4A) and b-wave (4B), when compared to age-matched control mice (n=7). 
Additionally, there was no significant difference in the amplitudes of the summated 
oscillatory potential component (4C) and P1-N3 flicker response (4D) between control and 
blast-exposed mice. 
Figure 5: Tear production analysis. Tear production was measured 10 months post blast 
exposure. No statistically significant difference was observed in the tear production between 
blast exposed mice (n=4) and age-matched controls (n=5).  
Figure 6: Chromatic PLR analysis in blast-exposed mice. Chromatic PLR analysis of blast 
exposed mice (n=12) showed significant deficits 24 h after blast exposure, using the red (630 
nm) and blue (480 nm) light compared to age-matched controls (n=9) (Fig 6 B, C). 
Chromatic PLR analysis of blast-exposed mice at 10 months post blast exposure (n=9) did 
not show statistically significant difference compared to response obtained from healthy 
(control) age-matched mice (n=5) (Fig 6 E, F). There was not a statistically significant 
difference in the resting pupil diameter of control or blast-exposed mice in scotopic 
conditions (Fig 6 A, D).  
Figure 7: OCT analysis following blast exposure showed mild but statistically significant loss 
in the peripapillary RNFL thickness (superior-temporal quadrant) in blast exposed mice 
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(n=5) when compared to the age matched controls (n=11). There was not statistically 
significant difference in the RNFL thickness for all other peripapillary quadrants, total retinal 
thickness or RNFL thickness in the area centralis region. Recordings were performed 3 
months post blast exposure.  
Figure 8: Histological evaluation of the retina from control and blast-injured mice show a 
near normal appearance. A reduction in cellularity of the retinal ganglion cell layer was 
observed, while all other retinal layers had a normal appearance.  
Figure 9: Electron microscopy of the optic nerve in healthy control mice demonstrates 
normal axonal appearance (A). Electron microscopy of the optic nerves of mice chronically 
after blast exposure (10 months post blast) shows reduced axon density (B). 
Figure 10: Proteins associated with oxidative stress are increased acutely after blast exposure. 
At 1 hour post blast, a significant increase in the expression of 4HNE was observed in the 
retina of blast-exposed mice (n=4) compared to age-matched controls (n=12) (A). At 1 hour 
post blast (n=12), there was a trend toward an increase in the expression of iNOS in blast-
exposed animals compared to healthy control mice (n=21), although this change was not 
statistically significant (B). At 1 hour post blast, retinal expression of beta amyloid in blast-
exposed mice (n=10) was significantly increased (p=0.03) compared to age matched controls 
(n=20) (C). No statistically significant difference was observed when 12 h (n=6) and 24 h 
(n=10) post blast exposure were added to the analysis.  
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CHAPTER V. GENERAL CONCLUSION 
The major findings of each research chapter included in this dissertation have been described 
and interpreted in the discussion section of each individual chapter. This section presents an 
overview of the results and findings of this dissertation. Comprehensively, we have 
successfully characterized optic nerve structure and function in healthy C57/bl6 mice, and we 
have applied similar techniques to study disease progression as a result of direct and indirect 
injury to the optic nerve. We have also confirmed that pERG is a sensitive and reliable tool to 
non-invasively study the functional progression of optic neuropathy in two different 
experimental models. 
Optic nerve structure and function in C57/bl6 mice 
We have longitudinally characterized the optic nerve function in healthy mice using pERG. 
Pattern ERG has been extensively used to study glaucoma24-28,  and recently, in Parkinson’s 
disease 304. In our study, no significant changes were observed in the pERG amplitudes and 
latencies of healthy mice at 3 months and 15 months of age. Chromatic PLR is a sensitive 
technique that can be used for monitoring early functional deficits in the retina/optic nerve. 
The utility of cPLR in association with ERG techniques may be a powerful method to 
accurately localize the source of retinal dysfunction. We have described in detail the normal 
pupil constriction values in C57/bl6 mice following exposure to red/blue light. We have also 
demonstrated that photopically matched blue light induces stronger pupil constriction 
compared to red light. These results are consistent with previously published data in different 
animal species34,247 and in humans212. Early SD-OCT studies used custom-made 
modifications to improve imaging for rodent retinas 305,306. However, with the advent of 
adaptive optics technology and the utility of 78D lens in SD-OCT 11, rodent retinal imaging 
can be performed with better resolution and sensitivity. In our study, SD-OCT analysis using 
25D lens consistently provided high resolution images of the fundus and the retinal layers. 
However, the automated segmentation of RNFL by the Spectralis software does not 
anatomically correlate for rodent retina, and manual segmentation is required to accurately 
reflect RNFL thickness. We have measured total retinal thickness and RNFL thickness in 
healthy mice, and our values for retinal thickness are consistent with previously published 
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mouse data using different OCT techniques and histology analysis 307. Altogether, these 
techniques can provide a good representation of retina/optic nerve structure and function. 
Optic nerve deficits in the experimentally induced PD mouse model 
We have observed significant deficits in pERG function with acute and sub-chronic 
treatments of MPTP, a toxin that has been previously reported to induce PD symptoms in 
humans 63 and animal models62. Furthermore, we have observed decreased amplitude of the 
oscillatory potentials (OP) in MPTP-treated mice using full-field ERG, although the 
combined scotopic responses of the ERG were normal. Reductions in OP amplitudes are 
likely a consequence of amacrine cell dysfunction or membrane damage to the dendritic 
processes of RGC308. Previous studies have demonstrated impairment of the retinal 
dopaminergic system in PD, which primarily results in abnormalities of amacrine cells and 
retinal ganglion cells dependent on dopamine as a neurotransmitter132,286-288. These 
observations, in combination with reduced dopamine content observed in the eyes of MPTP-
treated mice in our study, strongly suggest dysfunction of the anterior visual pathway as a 
result of dopaminergic impairment.  
The most interesting aspect of the study is a nearly complete protection of pERG function in 
PKCδ-/- mice treated with MPTP. PKCδ is an enzyme activated in response to oxidative 
stress events leading to an increased activation of caspase-3 and the subsequent pro-apoptotic 
cascade, which has been implicated in the degeneration of dopaminergic neurons 266,298. 
Further, a recent study has demonstrated that microglial activation also proceeds via a PKCδ-
mediated caspase pathway 309. These suggest the potential utility of PKCδ inhibitors in the 
treatment of PD-induced visual system abnormalities. In order to avoid the systemic side 
effects associated with current PKCδ inhibitors such as rottlerin, topical ocular treatment may 
provide an effective alternate toward the treatment of retina and optic nerve abnormalities in 
PD patients. 
Our results suggest that the pERG can be used as a sensitive diagnostic tool to monitor 
disease progression related to Parkinson’s disease in the retina. Furthermore, this approach 
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can be used to test the efficacy of therapeutic interventions targeting the retina and optic 
nerve in experimental animal models and human PD patients.                            
Optic nerve deficits following blast exposure in mice 
Acutely following blast exposure, we have observed significant deficits in cPLR and pERG 
analyses, which resolve soon afterwards. cPLR may be therefore be a useful technique for 
early screening of blast-exposed subjects exhibiting clinical signs of optic nerve injury. No 
significant changes were detected in the full field ERG parameters following blast exposure 
in our study. However, an interesting observation was that regardless of the age at which the 
mice were exposed to blast, mild but significant deficits in pERG P50-N95 amplitude 
persisted at 1 year of age. These results are contrary to the assumption that the effect of blast 
injury would be amplified by aging-associated dysfunction. However, it has been well-
established in ischemic stroke literature that although ischemic events are more prevalent in 
an aged population, tolerance for such events is also higher in this population310. It is 
believed that short, sub-lethal ischemic events can lead to the activation of protective 
mechanisms that provide tolerance to longer ischemic events which are normally lethal. Such 
adaptive defense mechanisms have been shown to involve genomic reprogramming311 and 
metabolic downregulation312 in the affected region. It is possible that similar tolerance 
mechanisms prevent the escalation of blast injury damage in aged animals. Identification of 
the underlying molecular events could potentially provide targets for therapeutic 
intervention. In addition to function loss, we have observed RNFL thinning 3 months post 
blast exposure. Many studies have reported visual dysfunction in veterans, which persists 
many years after exposure to blast injury 148,303. Our results support these findings, and based 
on our observations, it appears that the RGC and the optic nerve are the most susceptible 
ocular structures to blast exposure. We have also observed increased expression of oxidative 
stress-associated markers immediately following blast exposure. Altogether, these results 
suggest a role for mitochondrial dysfunction as a result of blast exposure, which can affect 
the optic nerve function due to its greater energy needs. Further, from our results, it appears 
that pERG and cPLR together are potentially useful diagnostic tools for the detection of 
blast-mediated optic neuropathy.  
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Future studies 
Based on the findings elaborated in this dissertation, undertaking the following studies could 
lead to the development of early diagnostic tools and therapeutic interventions for different 
forms of optic neuropathy.  
• Topical ocular treatment of PKCδ inhibitors in experimental PD models to study 
possible protective effects on retinal function 
• Testing the clinical utility of pERG as an early diagnostic parameter for PD patients 
• Testing the clinical utility of cPLR and pERG as screening tools for blast exposed 
subjects 
• Elucidation of compensatory mechanisms to protect retina/optic nerve function 
following blast exposure  
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